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ABSTRACT
THE ROLE OF MICRORNAS IN THE PATHOPHYSIOLOGY OF
NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY
Eric S. Peeples, M.D., Ph.D.
University of Nebraska, 2021
Supervisors: Zeljka Korade, Ph.D., D.V.M., Karoly Mirnics, M.D., Ph.D.
Neonatal hypoxic-ischemic brain injury (HIBI) is a devastating injury resulting from
impaired blood flow and oxygen delivery to the brain at or around the time of birth.
The subsequent metabolic failure and cellular injury in the brain can be partially
attenuated by rapid initiation of therapeutic hypothermia, but even with prompt
induction of hypothermia, more than one in four survivors suffer from major
developmental disabilities – an indication of the critical need for more effective
therapies. MicroRNAs (miRNA) may be able to act as therapeutic targets in
neonatal HIBI; however, very little is known about the endogenous expression of
miRNAs after neonatal HIBI nor the role that extracellular vesicle (EV)-delivered
miRNAs may play in the neuroprotective effects of EV administration. Using
temporal and regional sampling of brain tissue in a mouse model of neonatal HIBI
followed by next-generation miRNA sequencing (miRNA-Seq), miRNA profiles of
the different brain regions at 30 minutes and the whole brain at 24 and 72 hours
after injury were obtained. EVs were then modified to optimize neuroprotection by
hypoxia preconditioning, administered intranasally to the mouse model, and the
EV miRNA content was analyzed by miRNA-Seq. The studies identified several
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promising miRNAs for future investigations into miRNA-based therapeutic
interventions. Given the multifactorial nature of neonatal HIBI, it is likely that a
combination of miRNAs would need to be targeted to achieve maximal benefit.
Because of this, the list of promising miRNAs was grouped by targeted pathways,
and future investigations should consider assessing the effects of altering one or
more miRNA from each of the miRNA clusters. Additional mechanistic studies will
be necessary to demonstrate whether the differentially expressed miRNAs may be
beneficial or pathologic and whether the miRNAs detected in the EVs play a
significant role in the neuroprotection seen after hypoxia preconditioned EV
administration. Ultimately, given their broad effect profile, ease of administration,
and small size allowing for effective blood-brain barrier crossing, miRNAs
represent promising targets for improving brain injury and reducing developmental
impairments in neonates suffering from HIBI.
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INTRODUCTION
Pathophysiology of Neonatal Hypoxic-Ischemic Brain Injury
Neonatal hypoxic-ischemic encephalopathy – the clinical phenotype resulting from
perinatal hypoxic-ischemic brain injury (HIBI) – is estimated to affect on average 8 out of
every 1,000 live births worldwide, with some regions demonstrating rates as high as 15
per 1,000 live births (1). Therapeutic hypothermia has been shown to improve outcomes
in infants with HIE, but despite widespread utilization of therapeutic hypothermia in many
countries, more than half of infants with moderate to severe injury die or develop severe
neurodevelopmental disability (2). Because of this, there is an urgent need for the
development of targeted therapies to supplement therapeutic hypothermia in these highrisk infants.
Several similar but clearly distinct terminologies are used when discussing neonatal
hypoxia-ischemia. The first is asphyxia, which is the end-organ (i.e. brain, heart, kidney,
etc.) effects of hypoxia-ischemia on the newborn. HIE is the brain-specific effect of
asphyxia, and specifically refers to the clinical phenotype of abnormal brain activity
secondary to the hypoxic-ischemic injury. The clinical diagnosis of HIE relies on the
presence of signs of acidosis and hypoxia – such as low pH, elevated base deficit, or
severe fetal distress or hypoxia – as well as a number of clinical examination findings
suggesting abnormal brain activity and response. Since there is no clear definition of how
to determine encephalopathy in the animal models, pre-clinical studies rely on terminology
more specific to the abnormal brain pathology rather than brain activity or response. As
such, for animal models, terms such as HIBI are preferred. Lastly, cell culture models of
hypoxia-ischemia have been developed using the combination of oxygen and glucose
deprivation (OGD).
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Neonatal HIBI is a triphasic injury (3). The first phase starts with the initial hypoxicischemic insult, and the primary energy failure and hypoperfusion result in necrotic cell
death in the minutes to hours after injury. This phase generally terminates shortly after the
restoration of normoxia and adequate perfusion. The secondary phase starts between 6
and 12 hours after injury and continues until about 72 hours after injury. It is characterized
by deteriorating mitochondrial function and an acute inflammatory response, with
apoptosis being the hallmark cell death process during this phase. After the secondary
phase is the tertiary phase which includes partial recovery from the injury but is also
characterized by continued inflammation and gliosis (4). Importantly, between the primary
and secondary phases of injury is a latent phase during which time the primary energy
depletion has resolved, and the secondary metabolic failure has not yet occurred – this is
the target period for hypothermia, which currently the only proven therapeutic intervention
for neonatal HIE.
Therapeutic

hypothermia

has

been

shown

to

decrease

mortality

and

neurodevelopmental impairment in survivors of neonatal HIE. Cooling the entire body by
about 3 degrees Celsius for the first three days after injury decreases mortality and
neurodevelopmental impairment in survivors but has not been shown to be beneficial in
low- or middle-income countries (2, 5). Even in high resource settings, however, the
neuroprotection of hypothermia is incomplete. Based on the several moderate-size clinical
trials that have been performed to investigate hypothermia for neonatal HIE (6-13), 46%
of infants undergoing hypothermia still died or developed major disabilities, including 22%
of survivors developing cerebral palsy (2). Given the significant continued morbidity and
mortality after neonatal HIE, novel therapies are urgently needed. One promising area for
developing targeted therapeutic interventions in HIE is microRNAs (miRNA).

3

MicroRNA Synthesis and MicroRNA-Regulated Gene Expression
MiRNAs are small non-coding RNAs that modulate gene expression primarily through
post-transcription silencing of messenger RNAs (mRNA, Figure 1). MiRNAs average 22
nucleotides in length and are derived from the precursor primary miRNAs (pri-miRNA) that
are transcribed from DNA. The pri-miRNAs can be transcribed from introns of intragenic
regions (or less commonly intragenic exons) or intergenic DNA regions (14). MiRNA
genesis may occur through the
canonical pathway (Figure 1) or
one of several non-canonical
pathways that can be Droshaindependent

or

Dicer-

independent (15).
The canonical miRNA genesis
pathway starts with pri-miRNA
processing into pre-miRNAs by
the

microprocessor

complex

which consists of the RNA binding
protein

DiGeorge

Syndrome

Critical Region 8 (DGCR8) which
identifies the pri-miRNA binding
motifs

and

the

ribonuclease

enzyme Drosha which cleaves

Figure 1. Canonical pathway of mature microRNA
(miRNA) generation and RNA silencing. After
transcription, pri-miRNA are cleaved into pre-miRNA by
Drosha and DiGeorge Syndrome Critical Region 8
(DGCR8) before being transferred to the cytoplasm
where Dicer and transactivation response element
RNA-binding protein (TRBP) further cleave the premiRNA into a mature miRNA duplex. The mature
miRNA is then integrated with argonaute (Ago) proteins
in the RNA-Induced Silencing Complex (RISC) to inhibit
messenger RNAs (mRNA).

the base of the hairpin pri-miRNA
structure resulting in a two nucleotide 3’ overhang on the resulting pre-miRNA (16). The
pre-miRNA is then exported from the nucleus to the cytoplasm by the exportin-5 complex
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for further cleavage by the endonuclease Dicer and its cofactor transactivation response
element RNA-binding protein (TRBP) (17). This final cleavage step removes the terminal
loop and results in a mature miRNA duplex with a 5p strand derived from the 5’ end of the
pre-miRNA and a 3p strand from the 3’ end. Either strand can then be bound to argonaut
(Ago) proteins in an ATP-dependent manner (18); the selection of the strand for integration
with Ago depends on the thermodynamic stability at the 5’ end of the miRNA duplex or a
5’ U at the first nucleotide position (19).
The resulting miRNA-Ago complex is termed the RNA-induced silencing complex
(RISC). The RISC targets complementary sequences on mRNAs that are specifically
targeted by the miRNA guide strand in the RISC. These complementary sequences are
commonly on the 5’ untranslated region of the mRNA and are referred to as miRNA
response elements (MRE). The degree of complementarity between the MRE and the
miRNA in the RISC determines which of four silencing pathways the mRNA will undergo:
target cleavage, transient binding, stable binding, or Ago unloading (20).
Effects of Hypoxia-Ischemia on Human Cord Blood MicroRNAs
To date, there have been two studies that have attempted to profile the serum miRNA
changes in human newborns with HIE using high-throughput analyses (21, 22). Both of
these studies assessed only cord blood changes and both used the same cohort of infants,
but the studies used two different approaches to miRNA detection (next generation
sequencing versus microarray). Between the two studies, the investigators identified at
least 107 microRNAs that were significantly up- or downregulated in newborns diagnosed
with HIE. Due to differences in reporting the miRNA species (one of the manuscripts did
not regularly state which miRNA strand had altered regulation), it is difficult to exactly
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compare the two study results, though there were up to seven miRNAs that were found to
have altered regulation in the same direction in both studies (Table 1).
Of these, expression of miR-30b has also been confirmed to be decreased in the
Table 1. Umbilical cord blood microRNAs (miRNA) found to
have altered expression in both previous studies of human
neonates with hypoxic-ischemic encephalopathy (HIE). For
the direction of regulation, Up signifies upregulation of that
miRNA in HIE versus control; Down the inverse. The Looney
study did not specify the strand in their results, so definite
comparisons cannot be made between the two.
miRNAs

Looney, et al. 2015
Casey, et al. 2020
Possible Agreement Between Studies
miR-148a
Down
miR-148a-5p
Down
miR-16-2
Up
miR-16-2-3p
Up
miR-181a
Down
miR-181a-3p
Down
miR-21
Down
miR-21-3p
Down
miR-26b
Down
miR-26b-3p
Down
miR-30b
Down
miR-30b-5p
Down
miR-30c
Down
miR-30c-5p
Down
Possible Disagreement Between Studies
miR-106b
Down
miR-106b-5p
Up
miR-128
Down
miR-128-3p
Up
miR-192
Down
miR-192-5p
Up
miR-19a
Down
miR-19a-3p
Up
miR-19b
Down
miR-19b-3p
Up
miR-26b
Down
miR-26b-5p
Up
miR-27b
Down
miR-27b-3p
Up
miR-301a
Down
miR-301a-3p
Up

peripheral blood of neonates after HIE compared to controls and was strongly associated
with the platelet activation marker CD62P and the plasma fibrinolytic marker plasminogen
activator inhibitor 1 (PAI-1) (23). This study demonstrated persistent decreased
expression of miR-30b after the immediate time of birth; however, the kinetics of miR-30b
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expression are still not clear, as the precise timing of blood draw was not stated in this
study. Additionally, miR-148a has been found to also be down-regulated after adult
ischemic stroke (24), which is one of the closest relevant adult diseases to neonatal HIE.
Downregulation of miR-148a is associated with increased microglial activation and release
of inflammatory mediators such as tumor necrosis factor (TNF)-⍺, interleukin (IL)-1β, and
IL-10, likely through activation of mitogen-activated protein kinase (MAPK), extracellular
signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) (25).
Although not shown to be consistently altered in both of the high-throughput studies
described above, several additional miRNAs have subsequently been confirmed by
additional human studies. In a validation cohort, the same research team as the studies
above re-demonstrated decreased expression of miR-199a and -374a in infants
diagnosed with HIE versus controls (26). Downregulation of miR-374a in umbilical cord
blood was also confirmed by a separate research team (27). Additionally, the activin-A
receptor type IIb gene, which is a predicted target of miR-374a, has been shown to be
elevated in infants with severe HIE (though not moderate or mild) compared to controls
(28). Activin-A levels were not significantly different between groups.
An additional study by Looney, et al. evaluated umbilical cord blood levels of miR-181b
and its predicted target ubiquitin C-terminal hydrolase-L1 (UCH-L1) despite demonstrating
downregulation of miR-181b in only one of their three previous analyses (21, 22, 26). In
this most recent study, miR-181b was significantly downregulated in infants with moderate
to severe HIE compared to controls, and UCH-L1 mRNA was upregulated in infants with
HIE (29).
MiR-410 downregulation after neonatal HIE has also been subsequently confirmed in
circulating blood shortly after birth. Although only the Looney, et al study showed
decreased expression of miR-410 in their HIE cohort, Meng, et al recently demonstrated
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decreased expression of miR-410 in the circulating blood at around 6 hours after injury
(30). After subsequently testing overexpression of miR-410 in a cell culture OGD model,
they proposed that miR-410 and the beneficial effects of its upregulation are related to
interactions with phosphatase and tensin homolog (PTEN).
Probably the most well studied hypoxia-related miRNA is miR-210. Although neither
of the high-throughput studies of umbilical cord blood described above demonstrated
changes in miR-210, one study that measured only miR-374a and miR-210 in cord blood
did demonstrate significant decreases in both miR-210 and miR-374a expression in
infants with HIE versus healthy controls (27). For miR-210, however, the inverse pattern
was demonstrated in a recent study which showed increased miR-210 expression in cord
blood in infants with perinatal asphyxia (31), though this study did not separate those with
HIE and those with asphyxia without encephalopathy so the results may not be directly
comparable between the two studies.
With the only high-throughput studies performed to date being of cord blood, this has
allowed for relatively clean comparisons to be made between the study results, but has
limited the understanding of any changes occurring outside the immediate moments after
delivery (a time during which the insult continues to evolve and potentially progress).
Additionally, both of these studies were performed with the important aim of seeking out
novel microRNA biomarkers that could allow for early diagnosis and therefore potentially
more effective treatment for these high-risk infants, although there are several limitations
that must be considered when interpreting the umbilical cord blood miRNA expression
levels. The first is that cord blood is derived from shared circulation between both mother
and baby, especially when assessing very small molecules such as miRNAs that can
easily cross the placenta. There is a growing body of literature demonstrating that the
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development of the placenta and placental disorders significantly alter the circulating
miRNA profile of the mother in both humans and animals (32, 33).
Additionally, the human studies are understandably limited to only circulating blood
values (versus tissue values), so they are not specific to the brain. The findings from cord
blood studies could therefore vary considerably based on the amount of systemic organ
(heart, liver, kidney, etc.) injury that results from the hypoxic-ischemic injury. Even the
traditional laboratory markers of hepatic injury (aspartate transaminase, alanine
transaminase, prothrombin time, and activated partial thromboplastin time) as well as of
kidney injury (creatinine) can vary greatly between moderate and severe neonatal HIE
(34). An adequate biomarker would need to detect both moderate and severe HIE, as both
are thought to require treatment with therapeutic hypothermia. Due to the noise caused
by miRNAs produced by other organs, circulating miRNAs likely do not reflect brain injury
with the necessary specificity for an adequate biomarker.
Lastly, consistent with the triphasic nature of neonatal HIBI, miRNA expression also
varies over time after ischemic injury. Thought to be related to the multiphasic nature of
the expression of hypoxia inducible factor 1 subunit ⍺ (HIF1⍺) and other hypoxiaregulating genes after ischemia, several miRNAs have been shown to have multiple
phases of expression throughout the first 72 hours after injury. For instance, miR-335 was
shown to be downregulated in the first hours after middle cerebral artery occlusion,
followed by significant upregulation around 24 hours, and then downregulation again after
24 hours (35). As a consequence of this multi-phasic expression pattern, miR-335 mimic
has been shown to be neuroprotective when administered immediately after injury but
miR-335 antagonist was neuroprotective when administered at 24 hours after injury,
corresponding to inverse endogenous expression at each of those time points (35).
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MicroRNA Expression Profiles After Injury
No high-throughput miRNA analyses in neonatal HIBI have been performed outside of
the cord blood studies above; however, several studies have assessed individual miRNA
expression in the first hours or days after injury. One study in humans at 24-48 hours after
HIE demonstrated elevations in miR-21 that were associated with elevated HIF1 levels
(36). Another study assessed dried blood spot miRNA values at 18-19 hours after neonatal
HIE, demonstrating good correlation between dried blood spot levels and whole blood
samples, but showed no difference in any of the five miRNAs that they assessed: let-7b,
miR-21, miR-29b, miR-124, and miR-155 (37).
The expression of miR-210 outside of the immediate injury period has been evaluated
in a few studies, including one human study. In a study using a piglet model of HIBI,
plasma miR-210 increased from pre-injury to immediately post-injury by 3.5-fold, but was
then back to baseline levels by 30 minutes and remained near baseline at 9.5 hours after
injury (38). This study did not assess brain levels of miRNAs, which may explain the
difference between their findings and those of investigators evaluating brain miR-210
levels in the rat model of HIBI. In the rat model, studies have demonstrated significantly
higher brain miR-210 expression at 3, 6, 12, and 24 hours after HIBI compared to sham
operated normoxic control animals (39, 40). Specifically, miR-210 was significantly
upregulated in the microglia at 24 hours after injury (40). Another rat study demonstrated
decreased expression of miR-210 in the brain at 72 hours after neonatal HIBI compared
to controls (41). In the one human study specifically assessing miR-210 levels after the
immediate injury period, investigators demonstrated significant elevations (1.8-fold) of
peripheral blood miR-210 expression at 72 hours of life in infants who had suffered
perinatal asphyxia versus healthy controls (42), which was again inverse to the brainspecific levels seen in the rodent study.

10

Taken together, it is possible that the elevated miR-210 levels in the peripheral blood
at 72 hours in the human study but not at 9.5 hours in the piglet study may demonstrate a
delay in the detection of circulating miRNAs given the superior sensitivity of the brain
analyses. This would not account for the difference between the downregulation seen in
the brain in the rat study at 72 hours versus the upregulation in the circulating blood of the
humans at 72 hours, which may speak more to the lack of specificity of the circulating
blood microRNAs for detecting changes in brain-related miRNAs. Differences in technique
and species expression, however, must also be strongly considered.
In the cord blood study performed by Looney, et al, miR-374a was the most highly
downregulated miRNA in infants with HIE compared to healthy controls, which they
subsequently confirmed in a validation study (21, 43).

The decreased miR-374a

expression in cord blood was further demonstrated by another group, showing ~4-fold
decreased expression compared to healthy control newborns (27). Despite the consistent
downregulation in human umbilical cord blood, miR-374a levels were found to be
upregulated in the plasma of the piglet model after HIBI (38). Levels were elevated
immediately after injury, but then decreased rapidly so that, although still elevated at 30
minutes, were back to baseline by 3.5 hours after injury.
MiR-181a was also evaluated in the piglet model, with upregulation compared to
controls only at 1 hour after injury, but not before or after that time point (22). Of note, this
finding was inverse to what has been shown in the human cord blood studies.
Upregulation of miR-181a shortly after ischemic brain injury is supported by studies in
adult ischemic stroke demonstrating upregulation 30 minutes after injury in a rat model
(44), and reduced infarct size and improved neurological deficits when mice were
administered miR-181a antagonist at 60 minutes after injury (45). This protection may be
related to inhibitory effects of miR-181a on glucose-regulated protein 78, which is a heat
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shock protein found primarily in the endoplasmic reticulum (46). One potential issue with
using circulating miR-181a as a biomarker of ischemic brain injury, however, is that it is
not specific to the brain and has also been found to be upregulated after myocardial
ischemia (47), which may also occur after neonatal asphyxia. Additionally, in one study of
adult stroke, miR-181a was found to only be upregulated in the brains of male mice, with
no difference after injury in female mice (48).
Much like the miR-181a studies described above, several other investigators have
begun to investigate the therapeutic potential of altering miRNA expression before, during,
and after brain injury.
MicroRNAs as Therapeutic Targets for Hypoxic-Ischemic Brain Injury
MiRNAs are thought to play a significant role in modulating the neuroinflammation after
HIBI and therefore may act as effective targets for therapeutic intervention (49). Much of
the literature to date regarding miRNAs in neonatal HIBI has focused on a class of miRNAs
known as hypoxamiRs. HypoxamiRs, including the commonly studied miR-21 and -210
but also miR-335, -137, and -376c, are miRNAs that are regulated by hypoxia but also in
turn regulate cell response to decreased oxygen (50). These hypoxamiRs have been
shown to play a significant role in several pathological states, from cardiac injury to cancer
(51, 52), and altering miRNA levels in the brain may provide neuroprotection after HIBI
(35, 53, 54). Due to their small size (21-25 nucleotides in length), miRNAs are more likely
to cross the blood-brain-barrier than other larger molecules currently being tested as
therapeutics (55). As such, miRNA-based interventions may be able to provide targeted
therapy to supplement hypothermia in neonates suffering after HIBI, but the question of
which miRNA(s) to target remains a significant hurdle in the path toward developing
successful miRNA-based therapies.
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A few groups have attempted to modulate miR-210 expression to attenuate brain injury
after hypoxia-ischemia. In the one study of brain miR-210 levels described above, miR210 was persistently upregulated between 3 and 24 hours after injury (39). As such, most
of the interventional studies have attempted to decrease miR-210 through administration
of antagonists. In an adult stroke model, inhibition of miR-210 reduced stroke-induced
cerebral infarction and edema, decreased behavioral deficits after stroke, and suppressed
post-stroke inflammatory reaction when administered either prior to or 4 hours after injury
(56). Similarly, exosome-mediated delivery of miR-210 24 hours after stroke improved
survival and increased angiogenic factors (57).
In models of neonatal HIBI, miR-210 inhibition improves expression of glucocorticoid
receptors (39), suppresses microglia-mediate inflammation, in part through sirtuin 1 and
ten-eleven translocation 2 and subsequent increase of nuclear factor (NF)-kB (40, 58),
ameliorates mitochondrial dysfunction caused by miR-210-associated downregulation of
the iron-sulfur cluster assembly protein (59), and results in decreased cerebral edema and
IgG leakage into brain parenchyma, suggesting improvement in blood-brain barrier
integrity (60). Only one potentially contradictory study has been published in neonatal
HIBI, demonstrating decreased apoptosis after intracerebroventricular injection of miR210 mimic (61). The authors did not specifically state the timing of when the injections
were performed relative to the injury, however, making it difficult to truly compare their
results to the other studies that have all demonstrated consistent neuroprotective effects
of miR-210 antagonism.
Other miRNAs that have been successfully altered in neonatal HIBI include miR-374a,
-204, -124, and -454. Overexpression of miR-374a through intracerebroventricular
injection of miR-374a mimic attenuated brain injury and inhibited release of proinflammatory cytokines in neonatal rat model, potentially through NOD-, LRR-, and pyrin
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domain-containing protein 3 (NLRP3) inflammasome alteration (62). These effects could
also be related to alterations in the PTEN and phosphoinositide 3-kinase (PI3K) pathways
which have also been shown to be affected by miR-374a (50). Although there have been
some inconsistencies in post-injury levels of miR-374a between humans and animal
models, as described above, the beneficial effects of miR-374a overexpression would be
consistent with decreased levels seen in human umbilical cord blood. Similar
neuroprotective benefits have been demonstrated with the administration of miR-204
mimic, resulting in increased neuronal proliferation and decreased neuronal apoptosis
(63). Overexpression of miR-124 promoted cell survival and attenuated neuronal
apoptosis, resulting in improved testing of memory and neurological function at one and
two months after injury (64). Administration of miR-454 mimic improved cell viability in
OGD injured neurons, likely related to effects on suppression of tumorigenicity 18 (ST18)
expression (65), and lastly, knockdown of miR-326 upregulated the expression of the 𝛿opioid receptor, improved cell survival, and decreased caspase-3- and Bax-related
apoptosis (66).
When searching for therapeutic targets, it is important to note that the studies
performed on humans and piglets assessing the circulating miRNA levels were seeking to
discover biomarkers for diagnosis and prognosis – not therapeutic targets. As such, a
better understanding of the changes in brain miRNA levels after HIBI will be vital to the
future investigation of miRNA-based interventions. Supporting the disconnect between the
circulating levels and therapeutic promise, of the miRNAs that were described above as
having been tested in neonatal HIBI animal models and shown to have some benefit, only
miR-454 and -374a were shown to be altered in the human umbilical cord blood studies,
and neither miRNA was differentially expressed in both of the studies (21, 22).
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Free circulating miRNAs have a half-life that may be as short as 90 minutes (67).
However, miRNAs can be administered intranasally (39, 68), providing easy and efficient
brain delivery by bypassing the blood-brain barrier and minimizing possible off-target
systemic effects compared to intravenous administration (69). Several groups have
demonstrated that small RNAs can be successfully administered intranasally in rodent
models of brain injury, with adequate brain tissue penetration within 30 minutes after
administration of 0.5-1 nmol of miRNA (53, 68, 70). Another method to extend the miRNA
half-life and improve brain tissue targeting is by binding the miRNAs to nanoparticles to
decrease their uptake by the reticuloendothelial system or to insert the miRNAs into
protective vessels such as extracellular vesicles (EV).
Extracellular Vesicles and Other Therapeutic Vessels for MicroRNAs
EVs are a heterogeneous group of membrane-bound vesicles that are released by
various types of cells (71) and carry a variety of cargo including miRNAs, proteins and
lipids (72). EVs exist in the central nervous system, mediating interactions between
neurons and glia to support neuronal survival (73, 74). Due to their ability to cross the
blood brain barrier (75), they have become a strong candidate for both serum biomarkers
of brain injury as well as for therapeutic intervention. EVs derived from mesenchymal stem
cells (MSC) have been shown to decrease microgliosis and reactive astrogliosis in a rat
model of preterm inflammatory white matter injury after intraperitoneal injection (76). When
administered intravenously to a mouse model of adult stroke, MSC-derived EVs provided
improvement in neuronal survival and angioneurogenesis, with results similar to a
comparison group receiving MSCs (77).
EVs, as classified by the International Society of Extracellular Vesicles, range in
diameter from 20-1000 nm, and consist of several subclasses, including exosomes,
ectosomes, microvesicles, shedding vesicles, microparticles, exosome-like vesicles,
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nanoparticles, and apoptotic bodies (78). The importance of EVs lies in their ability to
mediate cell-to-cell communication; as such, they play significant roles in both normal
physiological processes as well as various pathological conditions.
The biogenesis of EVs occurs either dependent or independent of the Endosomal
sorting complex required for transport (ESCRT) pathway (79-81). In the ESCRT
dependent pathway, intraluminal vesicles (ILVs) are formed within large multivesicular
bodies (MVBs) by invagination of late endosomal membranes that then accumulate
proteins and cytosolic components or are trafficked to lysosomes for degradation (81).
The ESCRT-independent pathway has been shown to be mediated via raft-based
microdomains that are highly enriched in sphingomyelinases (82). Two lipid metabolism
enzymes (neutral sphingomyelinase and phospholipase D2) have been shown to
generate lipids in the limiting membrane of MVBs, which induce inward budding and, thus,
formation of ILVs in an ESCRT-independent manner (79, 80).
The composition of the EV is primarily governed by the physiological state of its
environment as well as the type of producer cell. While the membranes of all EVs are
enriched with cholesterol (83, 84), glycosphingolipids (83), and phosphatidylserine (84,
85), the exact lipid profile of specific EVs tends to be similar to, yet distinguishable from
that of its cell of origin (86). The nucleic acid content of EVs is also variable, including
various types and quantities of DNA, ribosomal RNA, mRNA, and non-coding RNAs such
as miRNAs.
It is now widely believed that much of the therapeutic benefits of stem cell
transplantation lies in the cell-to-cell signaling factors transported by EVs. The miRNA
cargo contained within the EVs are specifically and strongly associated with the positive
effects of stem cell transplantation. Although the EVs carry a range of potentially
therapeutic molecules including RNAs and proteins, a recent study demonstrated that
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administering mesenchymal stem cell-derived EVs to OGD-injured neurons decreased
apoptosis and improved cell survival; however, this protection was lost when the EVs were
pretreated with RNase but not when pretreated with proteinase (87). The ability of EVs to
carry wide therapeutic payloads makes them ideal candidates for this type of intervention.
EVs modified to overexpress certain miRNA have showed improved neurogenesis and
functional recovery in models of adult stroke (88, 89); however, no studies have been
performed in neonatal models.
Ischemic and/or hypoxic preconditioning has long been known to alter the cellular
environment in a manner that is protective against future hypoxic-ischemic injury. Given
the significant role that EVs play in intercellular communication, it is feasible that they may
also contribute to the protective effects of preconditioning. Supporting this theory,
investigators have demonstrated that infusion of preconditioned EVs resulted in significant
attenuation of infarct size in a mouse model of ischemic stroke compared to EVs that were
not preconditioned (90). The EV preconditioning not only affects several of the EV protein
markers, but also results in significantly altered miRNA profiles compared to naïve EVs
(91). This is consistent with studies of the brain tissue which have also demonstrated a
significant role of miRNA expression in the effects of preconditioning (92). Previous
studies have demonstrated that altering EV miRNA expression results in improved
therapeutic efficacy (93), but to date, no study has assessed the neuroprotective effect of
hypoxia preconditioned EVs after neonatal HIBI.
Gaps in the Current Literature
As described above, although some studies have begun to assess plasma levels at or
around the time of injury, very little is known about the brain miRNA changes after neonatal
HIBI. The studies that have been performed in the brain to date have focused only on one
or a few miRNAs, limiting the ability for identifying novel therapeutic targets. Given that
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the high-throughput studies of plasma samples have all been performed in the first
minutes or hours after injury, minimal known about any miRNA signaling outside the first
hours after injury. Additionally, HIBI does not affect all regions of the brain equally and,
although global brain expression patterns need to be investigated since miRNA-based
interventions are unlikely to affect only the injured tissue, investigations of brain regionspecific miRNA patterns may provide more sensitive insight into the roles miRNAs play in
neonatal HIBI.
Lastly, EVs are promising therapeutic vessels for several types of small molecules,
including miRNAs; however, no study to date has attempted to use intranasally
administered EVs for neuroprotection after neonatal HIBI. Although naïve stem cellderived EVs may provide some neuroprotection, there are emerging data to suggest that
preconditioning EVs with hypoxia may provide superior neuroprotection. Given the link
between EV miRNA contents and the beneficial effects of stem cell transplantation, it is
likely (but yet unknown) that the additional benefit of hypoxia preconditioned EVs may lie
in the miRNA content.
Dissertation Aims
In order to attempt to fill some of the gaps in the literature described above, the studies
included in this dissertation sought to address three specific aims.
The first aim was to evaluate the whole brain miRNA expression patterns at 24 hours
and 72 hours after HIBI in a neonatal mouse model. To attempt to differentiate the effects
of hypoxia alone versus combined hypoxia-ischemia, two control groups were used: one
true sham normoxia control and one sham control that was exposed to hypoxia but not
ischemia. Additionally, the contralateral HIBI expression pattern was analyzed given the
predilection of many studies to use the contralateral brain tissue as a sort of internal control
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in this animal model, but the lack of any description in the literature about the validity of
this practice for miRNA analyses.
The second aim sought to assess the brain region-specific miRNA expression patterns
at 30 minutes after neonatal HIBI and attempt to link alterations in miRNA expression with
mRNA changes. The 30-minute time point was chosen to attempt to maximize both the
comparability of the results to the human studies of umbilical cord blood (i.e. 0 minutes)
and the chances of demonstrating meaningful changes in expression given that previous
studies of piglets in the first hours after HIBI showed that the peak expression changes for
many miRNAs were around one hour after injury.
The third and final aim was to compare the neuroprotective effects of intranasal EV
administration after neonatal HIBI. For this aim, naïve neural stem cell-derived EVs were
compared with EVs derived from hypoxia-preconditioned brain tissue. EVs were
administered at 30 minutes and 24 hours after injury, and the effects of EV administration
on brain tissue viability and apoptosis were measured. To begin evaluating the mechanism
of EV-mediated neuroprotection, miRNA sequencing was performed on the hypoxiapreconditioned EVs.
Taken together, these aims seek to provide a comprehensive analysis of endogenous
miRNA signaling in the brain after neonatal HIBI in order to aid in identifying novel
therapeutic targets. Additionally, the final aim will begin evaluating the interplay EVinduced neuroprotection and the EV miRNA contents, thus confirming and/or expanding
on the number of potential therapeutic miRNAs.
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METHODS
Development of Mouse Models of Hypoxia and Hypoxic-Ischemic Brain Injury
All studies described were approved by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee.
Timed pregnant CD1 mouse dams were obtained from Charles River Laboratory
(Wilmington, MA). After delivery, pups were maintained in a 12-hour light and 12-hour dark
environment with the dam and littermates. At postnatal day 9, pups of both sexes were
randomized to the relevant injury/treatment groups for each study (Table 2). The HIBI
groups were induced with 5% isoflurane and then were anesthetized with 2.5% isoflurane
through a nose cone (VetFlo Anesthesia System, Kent Scientific Corp., Torrington, CT).
While under anesthesia, pups were labelled sequentially by tail tattoo. They were then
rotated to a supine position and the ventral neck sterilized with isopropyl alcohol and 2%
chlorhexidine. Analgesia was provided by injection of 2 mg/kg sterile bupivacaine at the
incision

site.

A

small

vertical incision was made

Table 2. Injury/treatment groups used throughout all
studies described here. HIBI, hypoxic-ischemic brain injury
induced by unilateral carotid artery ligation and 30 minutes of
8% oxygen; EV, extracellular vesicle; PBS, phosphate-buffered
saline; NSC, neural stem cell

in the midline of the ventral
neck.

The

neck

was
Chapter 1

dissected

in

order

to

identify and isolate the right
common

carotid

artery

(3 groups)
Chapter 2
(2 groups)

from the vagus nerve (94).
Chapter 3

After isolation, the common
carotid
cauterized,

artery
and

was
once

(5 groups)

Group

N

Sham

8 (4 at each time point)

HIBI

8 (4 at each time point)

Hypoxia only

8 (4 at each time point)

Sham

4

HIBI

4

Hypoxia only

3 (for brain EV extraction)

Sham + PBS

10 (6 TTC/protein; 4 TUNEL)

HIBI + PBS

10 (6 TTC/protein; 4 TUNEL)

HIBI + NSC EVs

10 (6 TTC/protein; 4 TUNEL)

HIBI + Brain EVs

10 (6 TTC/protein; 4 TUNEL)
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hemostasis was confirmed, the neck was closed with sterile surgical glue. Surgeries took
no longer than five minutes. The sham control group underwent the same anesthesia,
tattooing, analgesia, and neck dissection, but once the carotid artery was identified and
isolated, the neck was closed without vessel ligation. Hypoxia only groups also received
the sham surgery. After surgery, pups were transferred to a recovery cage.
During the surgery and the immediate recovery period, the pups were maintained at
normothermia on far infrared heating pads. The pups underwent serial examination every
ten minutes during and after the surgery until breathing, activity, and righting reflex
normalized. Once the pups were fully recovered, they were returned to the dam and
littermates for a two-hour recovery period. After recovery, groups were again separated,
and the HIBI and hypoxia only groups underwent 30 minutes at 8% oxygen in a hypoxia
chamber (BioSpherix, Parish, NY) at normothermia maintained by infrared heating pads.
The sham control group spent the same 30 minutes separated from the dam but in a warm
normoxic environment.
Tissue Collection and Storage
For the studies described in Chapter 1, half of the pups in each group were sacrificed
at 24 hours and the other half at 72 hours after injury. The whole brain was extracted as
quickly as possible, and the hemispheres separated. Each hemisphere was cut into 1 mm
coronal sections and then submerged in RNAlater Stabilizing Reagent (Invitrogen,
Carlsbad, CA) until RNA extraction. For hypoxia only and sham control groups, the right
hemisphere was used for analyses. For HIBI pups, ipsilateral (right) and contralateral (left)
hemispheres were processed separately. For the studies in Chapter 2, all pups were
sacrificed at 30 minutes after completion of hypoxia or normoxia. After dissecting out the
brains and separating the hemispheres, each hemisphere was further dissected into
regions. First, the brainstem was removed, and the cerebellum separated. The
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striatum/thalamus was then separated from the remaining tissue, exposing the
hippocampus, which was subsequently isolated from the cortex. Each region was
immediately frozen on dry ice and stored at -80°C until analysis.
For the studies in Chapter 3, 30 minutes after the second EV administration, the pups
underwent deep anesthesia isoflurane through a nose cone. The pups were then placed
supine and a bilateral thoracotomy performed to expose the heart. A 14-gauge needle
was inserted into the left ventricle followed by incision of the right atrium for drainage and
subsequent perfusion with 5-10 mL of ice-cold phosphate buffered saline (PBS). For 2,3,5triphenyltetrazolium chloride (TTC) staining and western blot, brains were immediately
dissected after PBS perfusion. For immunofluorescent histology, once the fluid from the
right atrium turned clear and the liver appeared pale, animals subsequently underwent
perfusion with 5 mL of 10% formalin. Following formalin perfusion and fixation, the brain
was removed intact and placed in a vial containing 10% formalin overnight. After formalin
fixation, the tissue was dabbed gently to remove excess formalin, washed twice with PBS,
and then placed in 15% sucrose for 12-24 hours and then placed in 30% sucrose.
Extracellular Vesicle Extraction from Brain Tissue
For the studies in Chapter 3, two groups of EVs were prepared: hypoxia
preconditioned brain tissue-derived (brain-EV) and neural stem cell (NSC)-derived EVs
(NSC-EV). NSC-EVs were extracted from an existing mouse induced neural progenitor
cell line (supernatant graciously provided by Dr. Yunlong Huang). The cell extraction and
tissue culture protocol has been described previously (95). Briefly, after NSC passage, the
NSC supernatant was collected for EV extraction, diluted in PBS, and transferred to an
ultracentrifuge tube. To prepare the brain-derived EVs, P9 CD1 mouse pups were
exposed to 8% oxygen for 30 minutes as described above. Immediately after hypoxia
exposure, the animals were sacrificed, and the brain tissue extracted and frozen at -80°C
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for EV extraction. The frozen brain tissue was finely minced in a tissue digestion solution
of papain and exosome-free Hibernate A (200-300 mg tissue with 3 mg papain and 3.5
mL Hibernate A) and incubated for 15 minutes at 37C. Enzyme digestion was stopped
using ice cold exosome-free Hibernate A. The homogenate was then centrifuged at 300 g
for 10 min at 4C and the supernatant transferred to an ultracentrifuge tube.
The brain-EV and NSC-EV suspensions both underwent ultracentrifugation at 100,000
g for 70 min at 4C. The pellet was washed with PBS and then underwent another round
of ultracentrifugation at 100,000 g. The supernatant was removed after the wash and the
pellet was resuspended in PBS and stored at -80C until use.

Evaluation of Extracellular Vesicle Characteristics
Standard EV characteristics have been proposed by the International Society for
Extracellular Vesicles (96). To ensure the necessary EV characteristics were present, first
the EV size, shape, and concentration were estimated by nanoparticle tracking analysis
(NTA) and electron microscopy (EM). NTA was performed on the NanoSight NS300
(Malvern Panalytical, Malvern, United Kingdom) as described previously (97). Samples
for EM imaging were spotted onto formvar/silicon monoxide coated 200 mesh copper grids
(Ted Pella Inc., Redding, CA). Grids were glow discharged for 60 seconds at 20µA with a
GloQube glow discharge unit (Quorum Technologies, Lewes, United Kingdom) prior to
use. Samples were negatively stained with NanoVan (Nanoprobes Inc., Yaphank, NY)
and examined on a Tecnai G2 Spirit TWIN (FEI Co., Hillsboro, OR) operating at an
accelerating voltage of 80kV. Images were acquired digitally with an AMT digital imaging
system. EV characteristics were also confirmed using protein electrophoresis and western
blot, as described below.
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Intranasal Administration of Extracellular Vesicles to Mouse Model of HIBI

At P9, pups were randomly assigned to one of four groups (Table 2): 1) unilateral right-

Figure 2. Procedure for intranasal administration of extracellular vesicles (EVs) in the
postnatal day 9 mouse model of hypoxic-ischemic brain injury. NSC, neural stem cell;
TTC, 2,3,5-triphenyltetrazolium chloride

sided carotid artery ligation followed by hypoxia and intranasal (IN) saline treatment; 2)
unilateral carotid artery ligation followed by hypoxia and IN administration of neural stem
cell-derived EVs; 3) unilateral carotid artery ligation followed by hypoxia and IN
administration of endogenous mouse brain EVs exposed to hypoxia; and 4) sham surgery
of carotid dissection without ligation followed by normoxia (21% oxygen) and IN saline
administration. Thirty minutes prior to EV administration, the nasal passages of the mice
were prepared by IN injection of 2 L of 2% hyaluronidase. Then 10 L of EV solution (8
x 109 EVs/ 10 μL) or PBS was administered to the mice intranasally, corresponding to
assigned treatment group. These intranasal administrations were performed 30 minutes
following hypoxia and repeated at 24 hours after hypoxia (Figure 2).
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Brain Tissue and Extracellular Vesicle RNA Extraction
For Chapters 1 and 2, between 15 and 20 mg of brain tissue at a time was thawed on
ice and transferred into a dounce homogenizer with Qiazol Lysis Reagent (Qiagen, Hilden,
Germany). The tissue was fully homogenized, and the RNA extracted using the RNeasy
Lipid Tissue Mini kit (Qiagen). Briefly, 200 μL of chloroform was added to each sample
and the tube shaken vigorously for 15 seconds followed by incubation at room temperature
for 3 minutes. The sample was then centrifuged at 12,000 x g for 15 minutes at 4C in
order to separate the aqueous phase containing the RNA from the organic and lipid
phases. The upper phase was transferred to a new tube and combined with one volume
of 70% ethanol and vortexed. The RNA was then extracted using the spin columns
supplied in the kit with serial buffer washes, on-column DNase digestion, and finally elution
of the RNA by addition of RNAse-free sterile water.
RNA concentration and integrity was determined through spectrophotometry (DeNovix
DS-11, Wilmington, DE). Only samples with ratios of 260/280 nm absorbance >1.9 were
used for analyses.
For Chapter 3, aliquots with 6.5 x 1015 EVs were mixed with Qiazol Lysis Reagent, and
the RNA extracted using the RNeasy Mini kit (Qiagen) as described above.
Next Generation miRNA Sequencing
For the miRNA sequencing performed in all three chapters, RNA samples extracted
from brain tissue (chapters 1 and 2) or from brain-EVs (chapter 3) underwent quality
confirmation through parallel capillary electrophoresis on a Fragment Analyzer (Agilent,
Santa Clara, CA) and then were processed for miRNA-Seq. MiRNA-Seq libraries were
prepared from 200 ng RNA per sample with the NEXTFLEX Small RNA Kit (PerkinElmer,
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Waltham, MA) per the manufacturer’s instructions. The libraries were then sequenced on
the Illumina NextSeq 550 platform (San Diego, CA).
mRNA Panel
For the mRNA analyses in Chapter 2, RNA samples underwent quality confirmation
through parallel capillary electrophoresis on a Fragment Analyzer (Agilent) followed by
the CodeSet Hybridization protocol with the nCounter Mouse Neuroinflammation probes
(Nanostring, Seattle, WA). Samples are hybridized by combining 8 μL master mix
(Reporter CodeSet and hybridization buffer), 5 μL of sample, and 2 μL of the capture
ProbeSet, and incubated overnight at 65C in a thermal cycler. The next morning, the
samples are transferred to the nCounter MAX/FLEX (Nanostring) device, where the
digital analyzer counts the fluorescent target molecules. Finally, data are downloaded
from the digital analyzer and loaded in nSolver for normalization and analysis.
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Quantitative Polymerase Chain Reaction (qPCR)
For Chapters 1 and 2, miRNA-Seq and mRNA panel findings were validated by qPCR
for the miRNAs and mRNAs that were highly differentially expressed and/or were
previously reported to have biological relevance in neonatal HIBI (Table 3). For miRNA
qPCR, the miRCURY LNA Reverse Transcription Kit (Qiagen) was used to generate
cDNA from 200 ng of RNA. Template RNA was adjusted to a concentration of 5 ng/μL and
2 μL was added to the reverse
transcription

mix

of

2

μL

reaction buffer, 4.5 μL RNasefree water, and 1 μL enzyme
mix, mixed, and incubated at
42°C for 60 minutes. The mix
was then heated to 95°C for 5
minutes

to

inactivate

the

enzyme, cooled back to 4°C,

Table 3. Sequences for each microRNA (miRNA)
messenger RNA (mRNA) quantitative polymerase
chain reaction primer
miRNA

Sequence (5’ to 3’)

miR-1195

UGAGUUCGAGGCCAGCCUGCUCA

miR-137-3p

UUAUUGCUUAAGAAUACGCGUAG

miR-155-5p

UUAAUGCUAAUUGUGAUAGGGGU

miR-2137

GCCGGCGGGAGCCCCAGGGAG

miR-335-5p

UCAAGAGCAAUAACGAAAAAUGU

miR-376c-3p

AACAUAGAGGAAAUUUCACGU

miR-6240

CCAAAGCAUCGCGAAGGCCCACGGCG

miR-665-3p

ACCAGGAGGCUGAGGUCCCU

mRNA
ATF3 Forward
Reverse

and stored at -20°C until use.

BDNF Forward
Reverse

The miRNA qPCR was
performed using the miRCURY
LNA SYBR Green qPCR kit
with

manufacturer

generated primers for each of
the

target

mature

miRNAs

ATTAGCGAGTGGGTCACAGC
TCAGTTGGCCTTTGGATACC
GAGCACCTGACCACAGAGTC

Reverse

CGAGTCGTTTGGCTGGGATA

FOS Forward
Reverse

Reverse
SOCS3 Forward
Reverse
SRXN1 Forward
Reverse

(Table 3). The cDNA solution

CAAAGGGTGTCAGGTTAGCAA

EGR1 Forward

NFKB2 Forward

(Qiagen)

CCAGGTCTCTGCCTCAGAAG

GGTGAAGACCGTGTCAGGAG
CCTTCGGATTCTCCGTTTCT
GGCCGGAAGACCTATCCTAC
AGGTGGGTCACTGTGTGTCA
GGTCACCCACAGCAAGTTTC
GGTACTCGCTTTTGGAGCTG
ATGTACCTGGGAGCATCCAC
GCTGCATGTGTCTTCTGAGC

was first diluted 1:60 in RNase-free water to a final volume of 600 μL and then added to a
pre-mixed reaction mix of SYBR Green Master Mix, PCR primer mix, and RNase-free
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water. The solution was mixed thoroughly, dispensed into PCR tubes, centrifuged briefly,
and then placed into the thermal cycler. Cycles were set for 2 minutes at 95°C for heat
activation, and then 40 cycles of alternating 10 second denaturation at 95°C and 60
seconds annealing at 56°C. Cycle threshold (Ct) values were downloaded from the device,
normalized to the U6 small nuclear RNA as an endogenous control, and analyzed. All
qPCR samples were run in triplicate.
For mRNA qPCR, a similar process was followed, but the RevertAid First Strand cDNA
Synthesis Kit (Thermo Scientific, Rockford, IL) was used for the cDNA synthesis and the
PowerUp SYBR Green Master Mix (Applied Biosystems, Waltham, MA) was used for the
standard qPCR. For mRNA analyses, values were normalized to the housekeeping gene
phosphoglycerate kinase 1 (PGK1). For both miRNA and mRNA analyses, Ct values and
expression levels were calculated by the ΔΔCt method (98). Expression fold-change in
the HIBI group compared to controls was reported after log 2 transformation.
Infarct Area Measurement
For the EV studies in Chapter 3, the PBS-perfused brains were immediately sectioned
into 2 mm coronal sections using an acrylic brain matrix (Kent Scientific). The section at
the optic chiasm (starting at 1 mm from the rostral aspect of the brain) was incubated in
2% TTC for 20 minutes at room temperature and then placed in 10% formalin for fixation.
Following this staining and fixation process, the TTC stained brain sections were scanned
and digitized. The area of viable non-infarcted tissue (seen as pink with the TTC stain) on
the ipsilateral hemisphere and the contralateral hemisphere were measured separately
using Image J software (NIH, Bethesda, MD). The percent of viable ipsilateral tissue was
estimated by dividing the ipsilateral area by the contralateral area.
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Protein Electrophoresis and Western Blot
For Chapter 3, protein electrophoresis and western blot were used both to characterize
EVs as well as for an outcome marker using homogenized brain tissue. For the brain
tissue analyses, the remaining ipsilateral brain tissue from the PBS-perfused brain was
homogenized in RIPA buffer with a dounce homogenizer. The total protein concentration
of the homogenate was analyzed by bicinchoninic acid (BCA) protein assay (Thermo
Scientific) and 20 ug of sample protein was prepared and loaded onto a pre-cast 4-12%
NuPAGE Bis-Tris gel (Invitrogen). For EV characterization, ~2.5 x 1014 EVs were loaded
into each well.
After electrophoresis, the protein was transferred to a PVDF membrane which was
then incubated with primary antibodies for caspase-3 (R&D Systems, Minneapolis, MN)
and beta-actin antibody (Invitrogen) for use as the loading control. EV characterization
membranes were incubated with calnexin (Invitrogen) or CD9 (Invitrogen) and beta-actin
primary antibodies. Following incubation, the membrane was washed and then anti-rabbit
IgG HRP-linked antibody (1:3000, Cell Signaling Technology, Danvers, MA) was added
and incubated at room temperature shaking for 60 minutes. The membrane was washed
again and developed in Radiance HRP substrate for chemiluminescence imaging on the
Azure 600 Western Blot Imaging System (Azure Biosystems, Dublin, CA). Band densities
were analyzed using Image J software as previously described (99) and normalized using
the band quantification of the beta-actin loading control.
Brain Tissue Sectioning
For Chapter 3, after formalin and sucrose fixation, the fixed brains were processed
for sectioning. First, the brains were placed in Optimal Cutting Temperature (OCT)
solution and re-frozen at -80°C. The tissue was then mounted to a specimen disk and 10
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μm sections obtained on a cryostat microtome (Leica Biosystems, Buffalo Grove, IL).
Sections were collected in PBS and stored at 4°C until staining.
TUNEL Staining and Brain Section Imaging
For terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining,
brain sections were post-fixed in a 2:1 mix of ethanol and acetic acid for 5 minutes and
then washed twice in PBS. The tissue was gently blotted with a laboratory wipe to remove
excess liquid and then immediately submersed in equilibration buffer for at least 10
seconds before removing buffer to apply terminal deoxynucleotidyl transferase (TdT)
enzyme and incubating at 37°C for one hour in a humidified chamber. After incubation,
the section was submersed in stop/wash buffer and incubated for 10 minutes at room
temperature. After washing, the section was placed in anti-digoxigenin conjugate solution
and then incubated for another 30 minutes at room temperature. Finally, the section is
washed in PBS at least four times and then stained with 4’,6-diamidino-2-phenylindole
(DAPI) as a nuclear counterstain. The sections were then covered in aqueous mounting
medium and a coverslip applied.
Fluorescent imaging was performed on the ImageXpress Pico Automated Cell Imaging
System (Molecular Devices, San Jose, CA). After obtaining images of each section, the
ImageXpress automated cell counting system was used to count TUNEL+ cells and DAPI+
cells in sections through the striatum (~3.5 mm from the rostral edge of the brain) using a
mouse brain atlas to determine landmarks for consistency between brains.
Bioinformatics and Statistical Analyses
For all miRNA sequencing, results were aligned to mature mouse miRNA from
miRBase using bowtie2 alignment, and differential expression analysis performed using
EdgeR. In Chapter 1, two samples with alignment <25% were excluded and replaced with
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new samples with alignment above 25%. A false discovery rate <0.05 or p-value <0.05 for
these exploratory studies were considered significant. Conservation between mammalian
species for each of the miRNAs was assessed using microRNAviewer (100). MiRNAs that
demonstrated >90% sequence homology between species were considered to be “highly
conserved.”
In Chapter 1, expression pattern relationships between controls, ipsilateral HIBI, and
contralateral HIBI, were assessed using a stepwise approach combining significance and
magnitude of change approach. First, miRNA species with an average raw count of <10
were filtered out, as these low expressors tend to give rise to more unreliable data. Then
counts per million (CPM) were calculated for each sample and the CPM was log2
transformed to establish differential expression for ipsilateral-control, ipsilateralcontralateral, and contralateral-control comparisons. For this analysis, differentially
expressed miRNA species were defined by an uncorrected p-value of 0.05 and a
magnitude change of 30% in at least one of the three comparisons. These data underwent
unsupervised two-way (gene vs. sample) hierarchical clustering based on Euclidian
distance using the Morpheus program (Broad Institute, Cambridge, MA). This procedure
was separately performed for samples obtained at 24 or 72 hours.
Correlation between high-throughput results (i.e. miRNA-Seq and Nanostring) and
qPCR results in Chapters 1 and 2 were performed using linear regression with Prism
version 9.2.0 (GraphPad, La Jolla, CA). Goodness of fit was determined using the R 2
value.
The miRNA KEGG pathway analyses in Chapter 2 were performed using Diana Tools
(101) using Tarbase annotations, a p-value threshold of 0.05, and enrichment analysis by
Fisher’s exact test with hypergeometric distribution. The mRNA Kyoto Encyclopedia of

31

Genes and Genomes (KEGG) pathway analyses were performed using Ingenuity Pathway
Analysis (Qiagen). For both analyses, pathway data were stratified by -log(p-value).
Network visualization of mRNA-mRNA and miRNA-mRNA networks in Chapter 2 were
obtained using Cytoscape (Institute for Systems Biology, Seattle, WA). The mRNAs
demonstrating significant differential expression in each region were mapped to the
BioGRID Mus musculus interactions archive (version 4.4.200). The nodes from the
significant mRNAs were selected, and networks were generated two degrees of
connection (undirected) between those mRNA and the other mRNA included in the
Nanostring Neuroinflammation panel. Those mRNAs with less than two connections were
excluded from the network. Node fill color relates to the log fold change of mRNA in
hypoxic-ischemic brain injury compared to controls. The same process was used for the
miRNA-mRNA networks, with the following exceptions. Starting with the miRNAs that
demonstrated significant differential expression, the miR2Gene pathway analysis (102)
was used to predict miRNA-mRNA interactions.
In Chapter 3, comparative analyses between the four injury/treatment groups were
performed using one-way analysis of variance (ANOVA) and the Mann Whitney U test for
individual group comparisons. P-values of <0.05 for ANOVA and <0.025 for Mann Whitney
test (Bonferroni correction for two comparisons – HIBI+PBS vs. each of the two EV
treatment groups) were considered significant.
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CHAPTER 1: TEMPORAL CHANGES IN MIRNA EXPRESSION
AFTER NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY
Material from: Peeples ES, et al, Temporal brain microRNA expression changes in a
mouse model of neonatal hypoxic-ischemic injury, published 2021, publisher – Springer
Nature.
Rationale
As most of the previous studies assessing endogenous miRNA expression after HIBI
were seeking to use miRNA expression as an early biomarker of injury, rather than
assessing for therapeutic targets, they have primarily used peripheral blood for miRNA
measurements (21, 22, 38, 103). As mentioned above, however, the circulating miRNA
levels are unlikely to adequately reflect the brain microenvironment given that the
peripheral blood contains miRNAs from every organ, not just the brain, and those results
should therefore be used with caution when attempting to identify therapeutic targets for
neuroprotection. Additionally, although it has been shown that gene expression may
remain altered as late as school age in children who suffered neonatal HIBI (104), previous
miRNA studies in neonatal HIBI have primarily focused on changes in the seconds (cord
blood) or first few hours after injury (21, 22, 38, 103).
The expression pattern of miRNAs changes rapidly in the first minutes to hours after
neonatal HIBI (22, 38) and clinically neonatal encephalopathy is often not diagnosed within
the first hour after injury (average age at entry to the large hypothermia trials ranged from
1.9 to 4.7 hours after injury (2)). As such, miRNA expression will likely have shifted
significantly from birth by the time that therapy is initiated. The miRNA expression patterns
in cord blood or immediately after injury in animal models, therefore, has limited utility in
the development of miRNA-targeted interventions that would most likely be administered
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over the course of hypothermia (approximately 2-72 hours after injury). Although some
studies have profiled the expression of a few selected brain miRNAs outside of the first
few hours after neonatal HIBI, the global profile of miRNA expression changes 24 to 72
hours after neonatal HIBI has not yet been established.
Designing interventions to effectively target miRNAs after neonatal HIBI will require a
greater knowledge of the subacute miRNA expression changes that occur after injury. To
that aim, the goal of this study was to assess changes in brain-specific miRNA expression
at 24 and 72 hours after injury in a mouse model of term neonatal HIBI. In order to provide
a comprehensive miRNA profile, next-generation miRNA-Seq was used and subsequently
validated by qPCR. The results of this study will provide important differential expression
information necessary to design future studies targeting miRNA expression in the first 72
hours after neonatal HIE.
HIBI Versus Hypoxia at 24 and 72 Hours After Injury
Analyses were performed between four different groups (Figure 3): normoxia controls,
hypoxia only, ipsilateral HIBI, and contralateral HIBI. Figure 4 demonstrates miRNAs with
significant differential expression in the first comparison: hypoxia only compared to
normoxia controls. This analysis demonstrated 51 miRNAs with significant differential
expression at 24 hours (Figure 4A), 129 at 72 hours (Figure 4B), and 38 at both time points
(Figure 4C). Thirty-three of the 38 that were altered at both time points were found to be
highly conserved between mammalian species. Notably, all miRNAs that were
differentially expressed at both time points after hypoxia only were expressed in the same
direction (positive or negative) at both time points.

34

Figure 3. Group comparisons made throughout temporal microRNA
study, with references to the relevant figures that contain each of the
comparisons. Hypoxic-ischemic brain injury (HIBI) model consists of unilateral
carotid artery ligation with 30 minutes of hypoxia at 8% oxygen. Sham surgery
includes dissection and visualization of carotid artery but no ligation. The
hypoxia only group received sham surgery followed by 8% oxygen for 30
minutes.

HIBI Versus Normoxic Controls at 24 and 72 Hours After Injury
A similar analysis was performed between the ipsilateral (lesioned) HIBI samples and
the normoxia controls (Figure 5). Figure 5A shows volcano plots for the miRNAs at 24 and
72 hours, providing a visual display of the number of miRNAs with a significant p value
and the associated log2 fold-change. Overall, 16 miRNAs were found to have significant
differential expression at 24 hours after HIBI (Figure 5B), and 26 at 72 hours after HIBI
(Figure 5C). Five of these miRNAs had significant altered expression at both 24 hours and
72 hours: miR-137-3p, -2137, -335-5p, -376c-3p, and -5126 (Figure 5D). The conservation
of miR-5126 has not been well described; however, the other four miRNAs are highly
conserved between mammalian species. Of note, miR-2137 and miR-5126 maintained
similar relative expression directionality at both 24 and 72 hours after injury (both were
upregulated at both time points after HIBI). MiR-335-5p, -137-3p, and 376c-3p
demonstrated multi-phasic expression, with all three being upregulated after ipsilateral
HIBI at 24 hours after injury but downregulated at 72 hours.
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To attempt to differentiate effects of hypoxia versus hypoxia-ischemia, Figure 6
demonstrates the miRNAs with significant differential expression at 24 and 72 hours after
HIBI compared to the differential expression in hypoxia only versus controls at each of the
time points. The five miRNAs that were differentially expressed after HIBI at both time
points are listed at the top of the figure (within the dashed box) for ease of comparison.
With only a few exceptions, the direction of expression after hypoxia only and HIBI were
similar between the two comparisons at 24 hours (Figure 6A) but were more often inverse
to each other at 72 hours (Figure 6B). Figure 6C is a Venn diagram demonstrating the
overlap of miRNAs with significant differential expression for the hypoxia only and HIBI
groups at each time point.
qPCR was subsequently performed on each of the miRNA-Seq samples to validate
the high-throughput findings. Figure 7 demonstrates strong correlation (R2=0.634)
between qPCR log2(fold-change) and miRNA-Seq log2(fold-change) for each of those
samples. miR-665 was an outlier for the correlated values, and subsequent post-hoc
exclusion of miR-665 values improved the R2 to 0.743. In addition to running qPCR on the
miRNA-Seq samples, three additional brains per group were used for qPCR, for a total of
6 samples per group. Figure 8 summarizes the total log2(ΔΔCt) fold-change qPCR results
for all six biological replicates in each of the analyzed miRNAs, compared to the miRNASeq log2(fold-change) values.
mRNA Pathways Associated with Dysregulated miRNAs
To aid in understanding the pathways affected by the upregulated miRNAs in this
study, a literature search was performed to identify the most commonly identified mRNAs
involved in neonatal HIBI; 63 such mRNAs were identified (listed in Table 4 (105-110)). A
list of miRNAs known to be associated with each of the mRNAs was obtained from
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Figure 4. MicroRNAs with significant differential expression in hypoxia only injury compared
to uninjured controls. Volcano plots demonstrate total number of microRNAs with significant p
values (above dashed line) and corresponding log2 fold-change. The microRNAs with significant
differential expression (defined by log 2 fold-change > 1, p value and/or false discovery rate < 0.05,
and average count per million reads > 10) are shown below, stratified by their altered expression at
B) 24 hours, C) 72 hours, and D) both.
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Figure 5. MicroRNAs with significant differential expression in ipsilateral hypoxic-ischemic
brain injury (HIBI) compared to uninjured controls. Volcano plots demonstrate total number of
microRNAs with significant p values (above dashed line) and corresponding log 2 fold-change. The
microRNAs with significant differential expression (defined by log2 fold-change > 1, p value and/or
false discovery rate < 0.05, and average count per million reads > 10) are shown below, stratified
by their altered expression at B) 24 hours, C) 72 hours, and D) both.
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Figure 6. MicroRNAs with significant differential expression in ipsilateral hypoxic-ischemic
brain injury (HIBI) compared to controls (black bars), with associated differential expression of
the same miRNAs in hypoxia only compared to controls (grey bars) at A) 24 hours or B) 72 hours.
The five microRNAs that were significantly differentially expressed at both time points are enclosed
in the dashed box. Significance defined by HIBI versus control comparison with log2 fold-change >
1, p value and/or false discovery rate < 0.05, and average count per million reads > 10. A Venn
diagram in C shows the number of significantly differentially expressed microRNAs under each
condition and time point.
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Figure 7. Correlation between next-generation microRNA sequencing (miRNA-Seq) and
quantitative polymerase chain reaction (qPCR) validation of eight highly expressed and/or
physiologically relevant microRNAs. The x-axis values are miRNA-Seq log2 fold-change (log2FC,
ipsilateral hypoxic-ischemic brain injury versus control) values and y-axis are qPCR ΔΔCt log2FC
values. Filled shapes are from the samples obtained at 24 hours and the open shapes are from
the samples obtained at 72 hours. The solid line represents the best-fit regression of the data
points with strong correlation (R 2=0.634) and the dashed line represents the ideal correlation
line (x=y). The top right and lower left quadrants contain the majority of samples, which all
demonstrated concordant log2FC directionality between miRNA-Seq and qPCR, while the top
left and lower right quadrants show the few samples with discordant directionality.

miRTarBase and then compared to the list of miRNAs with significant differential
expression from our study. Table 5 lists those differentially expressed miRNAs from our
study that were associated with one or more of the identified mRNAs, as well as the
experimental group and time point at which that miRNA demonstrated significant altered
expression.
Validity of Using Contralateral Brain as Control for HIBI miRNA Studies
Lastly, as contralateral brain tissue has often been proposed as a valid internal control
for unilateral HIBI models, the pattern of differential miRNA expression was evaluated
between the normoxia controls, ipsilateral HIBI, and contralateral HIBI groups using twoway, unsupervised hierarchical clustering. Figure 9 demonstrates the clustering results.
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Figure 8. Log2 differential expression values (ipsilateral hypoxic-ischemic brain injury
versus control) for next-generation microRNA sequencing (miRNA-Seq) and quantitative
polymerase chain reaction (qPCR) validation of eight highly expressed and/or physiologically
relevant microRNAs. Dashed lines demonstrate log 2>1 or <-1 significance thresholds.
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Table 4. Messenger RNAs (mRNA) associated with neonatal hypoxic-ischemic brain injury,
as identified by literature search (21-26). The mRNAs were matched with associated microRNAs
(miRNA) that demonstrated significant differential expression in the current study.
mRNA

Gene Name

Associated miRNA

Adam9

ADAM Metalloproteinase Domain 9

30e-5p, 362-3p, 140-5p

Adrb2

Adrenoceptor Beta 2

30e-5p

Alox5

Arachidonate 5-Lipoxygenase

None

Angpt14

Angiopoietin 14

None

Angpt2

Angiopoietin 2

None

Anxa2

Annexin A2

155-5p, 218-5p

Anxa4

Annexin A4

34a-5p

Atg10

Autophagy Related 10

192-5p, 362-3p

Bag3

BAG Cochaperone 3

34a-5p

Bdnf

Brain Derived Neurotrophic Factor

376b-5p, 15a-5p

Casp6

Caspase 6

34a-5p

Casp7

Caspase 7

192-5p, 106a-5p, 34a-5p, 23a-5p

Casp8

Caspase 8

29c-3p, 29b-3p, 29a-3p, 5119, 665, 34a-5p, 376b-3p

Chrm5

Cholinergic Receptor Muscarinic 5

None

Chrna5

Cholinergic Receptor Nicotinic Alpha
5 Subunit

None

Clcf1

Cardiotrophin Like Cytokine Factor 1

218-5p

Csf1

Colony stimulating factor 1

335-5p, 30e-5p

Csrnp1

Cysteine and Serine Rich Nuclear
Protein 1

None

Ctsc

Cathepsin C

375

Ctsl

Cathepsin L

362-3p

Ctss

Cathepsin S

None

Cyba

Cytochrome B-245 Alpha Chain

None

Cybb

Cytochrome B-245 Beta Chain

34a-5p

Cyp1b1

Cytochrome P450 Family 1
Subfamily B Member 1

340-5p, 148b-5p

Dap

Death Associated Protein

30e-5p, 335-5p

Ddx58

DExD/H-Box Helicase 58

218-5p, 3058-5p, 298-5p

Dusp1

Dual Specificity Phosphatase 1

101a-3p, 200c-3p

Dusp5

Dual Specificity Phosphatase 5

335-5p, 92a-3p

Eno2

Enolase 2

30e-5p, 93-3p, 1195, 665-3p, 218-5p, 669d-5p, 339-5p

F3

Coagulation Factor 3

223-3p, 375, 106a-5p, 335-5p

Fzd4

Frizzled Class Receptor 4

375, 192-5p, 29c-3p, 665

Gfap

Glial Fibrillary Acidic Protein

335-5p

Gria

Glutamate Ionotropic Receptor
AMPA

None
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Grik4

Glutamate Ionotropic Receptor
Kainate Type Subunit 4

335-3p, 339-5p

Grin2a

Glutamate Ionotropic Receptor
NMDA Type Subunit 2A

136-5p, 362-3p

Hspa12a

Heat Shock Protein Family A
Member 12A

15a-5p, 339-5p

Hspb8

Heat Shock Protein Family B
Member 8

193b-5p

Il11

Interleukin 11

None

Il13ra1

Interleukin 13 Receptor Subunit
Alpha 1

155-5p

Il1r1

Interleukin 1 Receptor Type 1

135b-5p, 192-5p

Il1rn

Interleukin 1 Receptor Antagonist

None

Il23a

Interleukin 23 Subunit Alpha

None

Il2rg

Interleukin 2 Receptor Subunit
Gamma

None

Junb

JunB Proto-Oncogene

155-5p, 3960

Lcn2

Lipocalin 2

None

Lrrc25

Leucine Rich Repeating Containing
25

None

Mapt

Microtubule Associated Protein Tau

136-5p

Nes

Nestin

155-5p

Nfat5

Nuclear Factor of Activated T Cells 5

30e-5p, 335-5p, 877-5p, 1a-3p, 106a-5p, 155-5p, 1493p, 1249-5p, 1195, 362-3p, 744-5p

Npy2r

Neuropeptide Y Receptor Y2

19b-3p

Nrp1

Neuropilin 1

335-5p, 338-3p, 218-5p

Ogfrl1

Opioid Growth Factor Receptor Like
1

192-5p, 665

Pdcd2

Programmed Cell Death 2

None

Procr

Protein C Receptor

375

S100a4

S100 Calcium Binding Protein A4

None

S100b

S100 Calcium Binding Protein B

29a-3p, 29b-3p

Scg2

Secretoneurin

362-3p

Spp1

Osteopontin

335-5p, 340-5p

Tlr1

Toll Like Receptor 1

335-5p

Tlr7

Toll Like Receptor 7

186-3p

Tmbim1

Transmembrane BAX Inhibitor Motif
Containing 1

362-3p

Tnf

Tumor Necrosis Factor

298-5p, 155, 223, 296-3p, 34a-5p

Uchl1

Ubiquitin C-Terminal Hydrolase L1

877-5p, 92a-3p, 218-5p
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Table 5. Differentially expressed microRNAs (miRNA) associated with one or more hypoxicischemic brain injury (HIBI)-associated messenger RNAs (mRNA) identified by literature
search. The direction of differential expression for each group, relative to controls, at each time
point (24 or 72 hours after injury) are designated by up (upregulation in HIBI versus controls) or
down (downregulation in HIBI versus controls) arrows.
Differential Expression
Hypoxia
miRNA
miR-1a-3p

24h

72h

↑

↑

HIBI
24h

72h
↓

↑

miR-101a-3p

Predicted mRNA Targets
Nfat5
Dusp1

↑

miR-1195

Eno2, Nfat5

miR-135b-5p

↑

↑

Il1r1

miR-140-5p

↑

↑

Adam9

miR-149-3p

↓

Nfat5

miR-15a-5p

↑

Hspa12a
↑

miR-155-5p
miR-19b-3p
miR-193b-5p

↓

miR-200c-3p

↓

miR-218-5p

↑

↑

Npy2r

↓

Hspb8
Dusp1

↑

miR-223-3p
↓

miR-23a-5p

Anxa2, Il13ra1, Junb, Nes, Nfat5, Tnf

↓

Anxa2, Clcf1, Ddx58, Eno2, Nrp1, Uchl1

↑

F3, Tnf

↑

Casp7

miR-29a-3p

↑

↑

Casp8, S100b

miR-29c-3p

↑

↑

Casp8, Fzd4

miR-296-3p

↓

Tnf

miR-298-5p

↓

Ddx58, Tnf
Adam9, Adrb2, Csf1, Dap, Eno2, Nfat5

miR-30e-5p

↑

↑

miR-335-5p

↑

↑

miR-338-3p

↑

↑

Nrp1

miR-34a-5p

↑

↑

Anxa4, Bag3, Casp6, Casp7, Casp8, Cybb, Tnf

miR-340-5p

↑

↑

↑

↓

↓

↑

miR-362-3p

Ctsc, F3, Fzd4, Procr

↑

Casp8

miR-669d-5p

↑

Eno2

miR-744-5p

↓

Nfat5

miR-877-5p

↓

Nfat5, Uchl1

miR-376b-5p

miR-93-3p

↑

Cyp1b1, Spp1
Adam9, Atg10, Ctsl, Grin2a, Nfat5, Scg2, Tmbim1

↑

miR-375-3p

Csf1, Dap, Dusp5, F3, Gfap, Grik4, Nfat5, Nrp1, Spp1, Tlr1

↑

Eno2
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These analyses revealed that the pattern of 107 miRNAs differentially expressed at 24
hours strongly separated the three experimental groups (vertical dendrogram in Figure
9A), with the normoxia control group showing the most distinct separation. It is notable
that the miRNA expression in the contralateral hemisphere was closer to the patterns seen
in ipsilateral HIBI than to the normoxia controls at 24 hours. In contrast, at 72 hours (Figure
9B), the contralateral HIBI samples appeared to demonstrate recovery, showing an
expression pattern with greater similarity to the miRNA profile in the normoxia controls. At
72 hours, a strong miRNA lesion signature started to emerge in the ipsilateral tissue,
providing greater separation from the other two groups. Comparisons between the miRNA
expression in the contralateral HIBI samples versus controls at 24 hours after injury are
also shown in Figure 10. Between the contralateral HIBI and control groups, there were
no miRNAs with significant differential expression at 72 hours after injury.
Summary
The results from this study provide a comprehensive assessment of the subacute brain
miRNA expression changes at 24 and 72 hours after hypoxia or HIBI, resulting in several
novel conclusions: 1) hypoxia alone results in significantly altered expression at both 24
and 72 hours of several miRNAs, many of which are hypoxamiRs; 2) HIBI resulted in
considerable phase-specific expression, with few miRNAs demonstrating significant
differential expression at both time points, and most of those demonstrating inverse
differential expression at 24 hours compared to 72; and 3) at 24 hours, most miRNAs with
significant differential expression had differential expression in HIBI similar in direction
(positive or negative) to hypoxia, but at 72 hours HIBI miRNAs tended to have inverse
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Figure 9. Two-way unsupervised clustering of differentially expressed microRNAs at 24
hours and 72 hours. Rows represent microRNA species and columns represent samples. Each
square represents an expression of a single microRNA species in a single sample, color-coded for
magnitude of change relative to other samples in the comparison. The unsupervised clustering A)
fully separated the control samples from the ipsilateral and contralateral hypoxic-ischemic brain
injury (HIBI) samples at 24 hours and B) clearly separated out the ipsilateral HIBI samples from the
control and contralateral HIBI samples at 72 hours after injury.
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Figure 10. MicroRNAs with significant differential expression in
contralateral hypoxic-ischemic brain injury (HIBI) compared to
uninjured controls. The microRNAs with significant differential
expression (defined by log2 fold-change > 1, p value and/or false
discovery rate < 0.05, and average count per million reads > 10) at 24
hours after injury. No miRNAs demonstrated significant differential
expression between these two groups at 72 hours.

directionality to hypoxia. Lastly, based on the relationships between the miRNA
expression in ipsilateral HIBI vs. contralateral HIBI vs. normoxia controls and found that
the ipsilateral injured brain was more similar to controls than was the contralateral brain
at 24 hours, though the contralateral brain became more similar to controls than ipsilateral
brain by 72 hours.
This study’s limitations included a modest sample size. Due to the exploratory and
descriptive nature of the study, the minimal number of samples that would provide for valid
statistical analyses were used for miRNA-Seq. In order to help overcome the lower sample
size for miRNA-Seq, however, qPCR was performed as a validation for several of the key
miRNAs. Due to the modest sample size, this study was unable to assess for differences
in expression between sexes, which may affect miRNA expression (111). Additionally,
given the descriptive methods, it was not possible to assess whether the alterations in
miRNA expression that were demonstrated were harmful and part of the pathophysiology
of the HIBI or were part of the endogenous cellular repair mechanisms. Lastly, this study
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used whole brain samples so cannot delineate possible region-specific miRNA expression
changes within the brain.
In conclusion, this study provides a global assessment of the subacute changes in
brain miRNA expression after hypoxia or HIBI in mouse models of injury. This is the first
study to include brain-specific miRNA sequencing as late as 72 hours after injury. As
investigators continue to advance research into targeted miRNA-based interventions for
neonatal HIBI, it will be very important to account for the multi-phasic expression patterns
that were observed in this study to identify optimal timing for the individual interventions.
One of the remaining gaps in knowledge relates to region-specific miRNA changes, which
will be addressed in the next study.
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CHAPTER 2: REGIONAL CHANGES IN MIRNA AND MRNA
EXPRESSION AFTER NEONATAL HYPOXIC-ISCHEMIC BRAIN
INJURY
Rationale
Although the study described in Chapter 1 provided for a description of the temporal
changes in brain miRNA expression after neonatal HIBI and demonstrated several
miRNAs with altered regulation in the brain as a whole, no studies to date have assessed
brain region-specific miRNA changes after injury. The brain has been shown to have a
unique baseline miRNA profile compared to other tissues, and each brain region also has
a specific expression signature (112). These baseline differences may result in
significantly different regional miRNA responses in disease processes, such as neonatal
HIBI, that tend to preferentially affect certain regions of the brain more than others.
Although all regions of the brain are exposed to the systemic hypoxia that is introduced
in the unilateral carotid artery ligation HIBI model, the reduction in blood flow resulting in
the ischemic injury does not affect all brain regions equally. In one of the initial descriptions
of this model by Dr. Vannucci, he described the most significant reductions in regional
blood flow as occurring in the striatum and thalamus (2-3 times the reduction seen in areas
such as the subcortical white matter), which correlated closely with the distribution and
extent of ischemic neuronal necrosis that was primarily seen in the striatum, thalamus,
and posterior cortical regions (113). At the same time, Dr. Vannucci’s group noted no
change or increased blood flow to the cerebellum and brainstem after HIBI in this model,
consistent with an injury produced by occluding only the anterior cerebral circulation
(carotid artery).
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Based on this knowledge of this variable blood flow distribution and injury, the goal of
this study was to evaluate the brain region-specific miRNA changes after neonatal HIBI in
the mouse model. The primary regions of interest were chosen from the literature
described above, and were the cortex, striatum/thalamus, and cerebellum. As described
in the introduction, most clinical and pre-clinical studies of miRNA profiling after neonatal
HIBI have assessed levels within the first hour after injury (21, 22). All of the human studies
were obtained immediately after delivery (i.e. cord blood) but the previous piglet models
demonstrated peak dysregulation of many miRNAs at one hour after injury. As such, to
allow for comparison with the previous clinical studies (of cord blood at 0 minutes after
injury) but also ensure time for miRNA dysregulation to occur (peak at 60 minutes after
injury), the region-specific miRNA levels assessed in this study were all obtained at 30
minutes after injury.
Regional Brain miRNA Changes 30 Minutes After Injury
Figure 11 demonstrates the miRNAs with significant differential expression after
neonatal HIBI compared to controls in each region. There were 39 miRNAs that were
differentially expressed in the cerebellum (16 upregulated; 23 downregulated), 12 in the
striatum/thalamus (11 upregulated; 1 downregulated), and 21 in the cortex (18
upregulated; 3 downregulated).
In all, 61 unique miRNAs demonstrated significant differential expression in one or
more region studied (Figure 12A); nine of which had significant differential expression in
more than one region. Of those miRNAs affected in multiple regions, miR-410-5p, -12643p, 1298-5p, -5126, and -34b-3p all had inverse differential expression in the cortex and
striatum/thalamus compared to the cerebellum, potentially suggesting specificity for
ischemia given that the cerebellum undergoes hypoxia but not ischemia in this model.
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MiR-6240, -3963, 3473a, and -3473b all had differential expression in the same direction
for the three regions, suggesting that they may be primarily affected by the hypoxic insult

Figure 11. MicroRNAs with significant differential expression at 30 minutes after
hypoxic-ischemic brain injury in the A) cerebellum, B) striatum/thalamus, and C) cortex.
Significance defined by fold-change > 1.5, p value and/or false discovery rate < 0.05, and
average count per million reads > 10.

(Figure 12B). The differentiation between cerebellar miRNA signaling and that of the
cortex, striatum, and thalamus was confirmed by two-way unsupervised clustering (Figure
12C) demonstrating a clear separation of three of the four cerebellum samples from those
of the other two regions.
Lastly, assessment of the canonical pathways that are predicted to be affected by the
miRNAs that were upregulated at 30 minutes after HIBI was performed by KEGG pathway
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analysis (Figure 12D). The KEGG analysis demonstrated that the miRNAs with altered
regulation in this study primarily alter metabolic pathways, including that of fatty acid
metabolism and biosynthesis, lysine metabolism, steroid biosynthesis, AMPK signaling,
and sphingolipid metabolism. Many of the traditional hypoxia and cell death pathways,
including mammalian target of rapamycin (mTOR), MAPK, and HIF1 were also included
in the KEGG analysis, but were lower in significance.
Regional Brain mRNA Changes 30 Minutes After Injury
In order to further evaluate the effects of miRNA alterations on mRNA levels in the
early period after HIBI, mRNA levels were also assessed at 30 minutes after injury using
the Nanostring Neuroinflammation Panel. Figure 13 shows the 44 mRNAs that were
differentially expressed in at least one region; 16 demonstrating significant differential
expression in two or more regions (Figure 13A). Of note, all mRNAs that had significant
differential expression demonstrated increased expression after HIBI relative to controls
(Figure 13B). Only a few mRNAs in the figure showed downregulation in any of the three
regions (for instance, Eomes in the cerebellum and cortex); however, in each case this
downregulation did not reach statistical significance.
KEGG mRNA pathway analysis demonstrated that the mRNAs that are upregulated
at 30 minutes after HIBI are largely involved in inflammatory and cell death pathways,
including interleukin (IL-3, -8, -10, -17A), TNF receptor, HIF1⍺, and PI3K signaling (Figure
13C). For the mRNA KEGG analysis, 335 pathways were identified as significant; the top
50 were included in the figure.
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Figure 12. MicroRNAs (miRNA) with significant differential expression in more
than one region. A) Venn diagram demonstrating the number of miRNAs with
significant differential expression and the overlap between each region; B) differential
expression of the nine miRNAs with significant differential expression in more than one
region (*regional expression significant, as defined by fold-change > 1.5, p value < 0.05,
and average count per million reads > 10); C) two-way unsupervised clustering of
differentially expressed microRNAs demonstrating separation of the majority of the
cerebellum samples from the cortex and striatum/thalamus samples. Rows represent
microRNA species and columns represent samples. Each square represents
expression in a single sample, color-coded for magnitude of change relative to controls;
and D) KEGG pathway analysis of the miRNAs with significant differential expression.
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Figure 13. Messenger RNAs (mRNA) with significant differential expression in
more than one region. A) Venn diagram demonstrating the number of mRNAs with
significant differential expression and the overlap between each region; B) differential
expression of the mRNAs with significant differential expression in at least one region
(significance defined by fold-change > 1.5 and p value and/or false discovery rate <
0.05); and C) KEGG analysis demonstrating the canonical pathways affected by all of
the mRNAs demonstrating significant differential expression.
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mRNA-mRNA Networks
Figure 14 demonstrates the mRNA-mRNA network connections between those
mRNAs with significant differential expression 30 minutes after HIBI and up to two degrees
of connection with the other mRNAs analyzed in this study. The differentially regulated
genes that were consistently demonstrated to be highly integrated into all three regional
networks included Atf3, Fos, Arc, Jun, and Tlr.

Figure 14. Messenger RNA (mRNA) networks in each region representing the
mRNA with significant differential expression after hypoxic-ischemic brain injury versus
controls and two degrees of connection between those mRNA and the other mRNA
analyzed in this study. Not shown are any mRNAs with no, or only one, connection.
Node fill color relates to the log fold change of mRNA in hypoxic-ischemic brain injury
compared to controls.
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Networks of miRNA-mRNA Interactions
Two miRNA species that were significantly differentially expressed in the cortex were
closely associated with mRNAs that were also found to have significant differential
expression: miR-1195 and -690 (Figure 15). MiR-1195 was associated with Tnfsf10b and
miR-690 with Egr1. There were no significant miRNA-mRNA networks in either the
striatum/thalamus or the cerebellum.
qPCR Validation of Nanostring Analyses
For validation of high-throughput mRNA data, qPCR was performed on each of the
samples for seven of the mRNAs with significant differential expression. Figure 16 shows
very strong correlation (R2=0.894) between the Nanostring values and the qPCR values
for all three regions and all seven mRNA species.

Figure 15. MicroRNA to messenger RNA (miRNA-mRNA) networks in the cortex.
The only two miRNAs that demonstrated significant differential expression at 30 minutes
and were closely linked to mRNAs also significantly altered at 30 minutes after injury
were miR-1195 and -690. Neither the striatum/thalamus nor cerebellum expression data
resulted in significant miRNA-mRNA networks
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Figure 16. Correlation between Nanostring RNA sequencing and quantitative
polymerase chain reaction (qPCR) validation of seven highly expressed mRNAs. The x-axis
values are Nanostring log2 fold-change (hypoxic-ischemic brain injury versus control) values
and y-axis are qPCR ΔΔCt log2FC values. The solid line represents the best-fit regression of
the data points with strong correlation (R2=0.894) and the dashed line represents the ideal
correlation line (x=y).

Summary
This study represents the first brain region-specific profiling of miRNA expression after
neonatal HIBI, finding 61 unique miRNAs with significant differential expression in at least
one of the three regions studied. Additionally, Nanostring mRNA panel analyses were
performed in order to attempt to link the miRNA changes that were seen to alterations in
relevant mRNA pathways. Only two miRNAs were found to have direct pathway links to
the mRNAs with significant differential expression, underscoring the differences in
pathway targeting that were seen between the mRNAs and miRNAs. While the altered
mRNAs were mostly made up of immediate early genes (IEG) such as Fos, Jun, and Arc
that were associated with downstream inflammatory and apoptotic pathways on KEGG
analysis, the miRNAs that demonstrated significant differential expression were mostly
associated with pathways of metabolism and synthesis. Although any conclusions
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regarding pathway analyses must take into consideration the somewhat limited scope of
the mRNA analyses (using a specific panel rather than whole genome analyses), these
data suggest differing roles of mRNAs versus miRNAs in the first 30 minutes after neonatal
hypoxic-ischemic brain injury.
Additionally, in the previous study (Chapter 1), we demonstrated that the contralateral
brain has limited utility as an “internal control” for miRNA studies in this model. The
cerebellum in this study, however, demonstrated a unique miRNA profile from either of the
other two regions (Figure 12C). This difference could potentially be caused by
maturational differences between cerebellar and that of the rest of the brain (114), but is
likely due at least in part to its sparing from the ischemic injury induced by the carotid
artery ligation (113). Although this study only assessed the miRNA profiles at 30 minutes
after injury, the findings here would suggest that the cerebellum may act as an adequate
internal control at least in the first hour after injury.
There are a few limitations to this study that warrant discussion. They include a lack
of a hypoxia-only control group. Though it may be reasonable to consider the cerebellum
group as a hypoxia-only group, in comparing the cortex and striatum/thalamus data to the
cerebellum it is not possible to separate whether differences are related to the inter-region
differences or due to differences between hypoxia only and HIBI. Additionally, the mRNA
analyses in this study were limited to only those mRNAs included in the Nanostring
Neuroinflammation panel. Although this panel contains 770 genes relevant to
neuroinflammation and brain injury, the network analyses performed were restricted to
only those genes in the panel. Lastly, we were unable to study individual hippocampal
sections due to low RNA yield. Future studies assessing hippocampal RNA signaling in
this model could consider pooling samples.
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In conclusion, this study demonstrated that miRNA expression varies by brain region
after neonatal HIBI, and that the cerebellar miRNA profile is clearly distinct from those of
the striatum/thalamus and cortex. Although miRNA-mRNA interactions may play more
significant roles outside of the immediate period after HIBI, most of the mRNA with
significant differential expression in this study were IEGs associated with downstream
inflammatory and cell death pathways that were mostly distinct from the miRNA-targeted
metabolic pathways. Future studies assessing brain miRNA expression to guide therapy
development should consider evaluating individual brain regions rather than whole brain
to ensure the sensitivity needed for targeted therapies.
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CHAPTER 3: MIRNA CONTENT OF NEUROPROTECTIVE
HYPOXIA-PRECONDITIONED EXTRACELLULAR VESICLES
Rationale
MSC transplantation has been shown to be a feasible and effective therapy for
neonatal hypoxic ischemic brain injury in animal models (115). Significant concerns about
the short- and long-term safety of MSC transplantation in this population remain, however,
including associated risks of immunogenicity, proliferation, embolus formation, and
malignant transformation (115-117). It is now widely believed that the stem cells elicit their
therapeutic effects through paracrine signaling by several mechanisms including stem
cell-secreted EVs that act as carriers to deliver protein, RNA, and miRNA contents to
injured tissue (118-121). As such, EVs have recently been evaluated as potential therapy,
with several studies demonstrating neuroregenerative potential and decreased brain injury
following hypoxia-ischemia (115, 121), even when compared to therapy with MSCs (122).
Additionally, EVs have not been associated with the same immunological or neoplastic
risks as cell transplantation.
EVs are believed to be tissue-specific, and brain cells such as neurons and
oligodendrocytes demonstrate preferential uptake of EVs derived from other neurons or
microglia, respectively (121, 122). Given this potential for preferential uptake, EVs derived
from NSCs and other brain-derived cells may provide increased specificity and more
efficient targeting of the injured cellular environment than EVs derived from MSCs or other
non-brain cells. Recent evidence supports that NSC-EVs exhibit more potent therapeutic
potential than MSC-derived EVs in regenerative outcomes following thromboembolic
stroke (118). In addition, most of the studies of MSC- and NSC-derived EVs have utilized
naïve cultured cells grown in physiological conditions. It has been shown that the contents
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of EVs are altered in response to hypoxia and brain injury (123, 124), however, and this
EV conditioning in response to injury may allow for their contents to be altered in a manner
that allows for even more specific targeting to hypoxia-ischemia injured brain tissue.
This study seeks to evaluate the effects of intranasal (IN) administration of naïve
NSC-EVs on a mouse model of neonatal hypoxic-ischemic brain injury. Previous studies
have demonstrated successful brain uptake of intranasally-administered EVs, with wide
anatomic distribution (125), including neurons and microglia in the forebrain (126),
hippocampus (127), and cortex (128). The neuroprotective effects of these naïve EVs
will be compared to those of EVs derived from mouse brain tissue that has been
preconditioned with hypoxia to potentially stimulate EVs with contents more specific to
the hypoxic-ischemic brain. Understanding the comparative neuroprotective effects of
NSC-EVs and brain-derived EVs following HIBI will allow for more targeted EV-based
therapies in the future with the goal of improved lifelong outcomes for neonates with HIE.
Confirmation of Extracellular Vesicle Characteristics
All EVs underwent standard characterization to confirm EV features were present.
Both the NSC-EVs and brain-EVs were positive for the EV marker CD9 and negative for
calnexin (Figure 17A&B). EM demonstrated classic cup-shaped EV morphology (Figure
17C). Nanoparticle tracking analysis of the undiluted EV suspensions showed a
concentration of 8.42 x 109  3.28 x 108 particles/mL of NSC-EVs and 1.27 x 1013  8.65
x 1011 particles/mL of brain-EVs. Both EV populations were primarily 80-300 nm in size
with peaks between 152 and 208 nm (Figure 17D).
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Figure 17. Confirmation of extracellular vesicle (EV) characteristics by western blot of EVs
and whole brain homogenate (Hom) as a positive control for A) the EV marker CD9 and B) the
EV negative control calnexin; C) Electron microscopy demonstrating intact cup-shaped EVs;
and D) nanoparticle tracking analysis of EV size distribution for both brain-derived and neural
stem cell-derived (NSC) EVs.

Infarct Size Comparison
TTC staining of coronal brain sections at the level of the optic chiasm demonstrated
significantly more ipsilateral viable tissue between the HIBI + PBS group and the HIBI +
brain-EV group (mean 28% and 72%, respectively, p=0.004) (Figure 18). The HIBI + NSCEV group also demonstrated increased viable tissue, but this did not reach statistical
significance (p=0.052).
Apoptosis as Measured by Caspase Signal and TUNEL Staining
Relative quantities of the apoptotic protein caspase-3 and its cleaved version were
detected by western blot (Figure 19). No differences were seen between the HIBI + PBS
group and the HIBI + NSC-EV group in either the cleaved form (p=0.372) or intact form of

62

caspase-3 (p=0.999). The brain-EV group, however, had significantly less cleaved
caspase-3 (p=0.015) and a non-significant trend toward less intact caspase-3 (p=0.026).
TUNEL staining of the ipsilateral striatum demonstrated a non-significant decrease in
the percent of TUNEL+ cells in both the NSC EV and brain EV groups versus the HIBI
group (Figure 20A&C). This trend was similar when assessing both the combined
ipsilateral striatum and cortex regions (Figure 20B).
miRNA Measurement of Hypoxia-Preconditioned Extracellular Vesicles
Next generation miRNA sequencing was performed on four samples of hypoxiaconditioned brain EVs. Twenty-four miRNA species were detected, with six of the species
detectable in all four samples (Figure 21A). Of the miRNAs that were detectable in at least
two of the four samples, miR-342-3p, -125a-5p, -330-3p, -128-2-5p, and -182-5p have all
been shown to be altered in the first 24 hours after neonatal HIBI in animal models
(including the studies described above in Chapters 1 and 2) (22, 38, 129). Additionally,
miR-92b-3p, -328-3p, and -342-3p were each shown to have altered expression in
umbilical cord blood of infants diagnosed with HIE (21, 22).
To assess whether the miRNA contents could be related to the anti-apoptotic effects
seen with brain-EV administration, a KEGG pathway analysis was performed for the
miRNAs expressed in the brain-EVs (Figure 21B). The significantly associated pathways
included several anti-apoptotic pathways such as forkhead box O (FoxO), Hippo,
transforming growth factor (TGF)-β, MAPK, and HIF1 signaling, as well as the caspase3-related cGMP-dependent protein kinase G (cGMP-PKG) signaling pathway.
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Figure 18. Measurement of relative tissue infarct area, using A) representative 2,3,5triphenyltetrazolium chloride (TTC) staining of coronal brain tissue sections in each intranasal
treatment group, demonstrating viable tissue (pink) and infarcted area (white) in order to
calculate B) the percent viable tissue in the ipsilateral hemisphere, calculated as area of viable
tissue on ipsilateral side divided by area of viable tissue on contralateral side. *p=0.004;
**p=0.052 EV, extracellular vesicles; HIBI, hypoxic-ischemic brain injury; NSC, neural stem cell;
PBS, phosphate-buffered saline
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Figure 19. Signal ratio of caspase-3 and cleaved caspase-3 to -actin control. A)
Representative images of western blots demonstrating B) a non-significant trend toward
increased caspase-3 and C) significantly increased cleaved caspase-3 signal in the hypoxicischemic brain injury (HIBI) + hypoxia-preconditioned brain extracellular vesicles (EVs)
compared to HIBI + phosphate-buffered saline (PBS). *p=0.026; **p=0.015 NSC, neural stem
cell
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Figure 20. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining for apoptotic cells between treatment groups obtained in sections ~3.5 mm
posterior to the rostral brain edge. A) Representative images of the striatum with green
TUNEL+ cells and blue DAPI TUNEL- cells; B) Analysis of the entire ipsilateral hemisphere, with
the percent of cells positive for TUNEL stain versus DAPI positive cells; and C) analysis of only
the ipsilateral striatum. HIBI, hypoxic-ischemic brain injury; PBS, phosphate-buffered saline; EV,
extracellular vesicles; NSC, neural stem cell
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Figure 21. MicroRNAs (miRNA) expressed in hypoxia-preconditioned
extracellular vesicles (EV). A) List of miRNAs sorted by relative counts and
described as median (min-max) count per million (CPM) reads in each sample; and
B) KEGG pathway analysis of the miRNAs that were detectable in the hypoxia
preconditioned brain-derived EVs. *MiRNA that has been previously demonstrated
to be altered after neonatal HIBI in one or more human study †MiRNA that has been
previously demonstrated to be altered after HIBI in one or more animal study,
including the current studies.
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Summary
These data suggest that treatment with intranasal extracellular vesicles (EVs) may
confer neuroprotection following neonatal HIBI. Although IN administration of naïve NSCderived EVs resulted in non-significant decreases in infarct size and caspase-3 levels,
treatment with hypoxia-preconditioned brain-EVs resulted in a marked increase in
ipsilateral viable tissue and decrease in cellular apoptosis after HBI. Some of the
neuroprotective benefits of the brain-EVs may be related to their miRNA contents, many
of which are involved in apoptotic pathways. These results demonstrate not only the
therapeutic potential of pre-conditioned EVs but also that the EV contents may play a role
in their neuroprotective effects.
This study primarily assessed apoptosis through the evaluation of the apoptotic marker
caspase-3. However, the generation of free radicals and inflammation through the
expression and activation of pro-inflammatory cytokines are also involved in the
pathogenesis of HI brain injury (130-133). MSCs and NSCs have both shown inhibitory
effects on mediators of inflammation and oxidative stress (134, 135). Although
neuroapoptosis was the primary focus of this study, future studies assessing the effects
of EV administration could assess other potential drivers of the neruoregenerative effects.
An additional limitation to the current study was the lack of dose response assessment,
as only a single dose level of EVs (given in two separate administrations) was used in this
study. Moving forward, a dose-escalation study would be beneficial to optimize dosing and
maximize regenerative potential.
Currently, therapeutic intervention for HIE in neonates is restricted to hypothermia,
which provides limited effect. The results from this study demonstrated regenerative
potential of EVs, particularly hypoxia-preconditioned brain-derived EVs. Further analyses
of the contents of hypoxia-preconditioned EVs could allow for engineering of EVs with
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optimal miRNA, RNA, and protein content to provide for a targeted cell-free therapy that
could potentially improve the neurodevelopmental outcomes in infants diagnosed with
HIE.
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DISCUSSION
Overall, the studies described above provide a comprehensive analysis of the spatial
and temporal endogenous brain miRNA signaling after neonatal HIBI as well as identifying
miRNAs included in the neuroprotective hypoxia preconditioned EVs.
Chapter 1 provided a comprehensive assessment of the subacute brain miRNA
expression changes at 24 and 72 hours after hypoxia or HIBI, including the identification
of 16 miRNAs that had significant differential expression at 24 hours after HIBI, 26 at 72
hours, and five (miR-137-3p, -2137, -335-5p, -376c-3p, and -5126) which had significant
altered expression at both 24 and 72 hours. Chapter 2 then provided brain region-specific
profiling of miRNA expression at 30 minutes after neonatal HIBI, finding 61 unique
miRNAs with significant differential expression in at least one of the three regions studied;
most of which were associated with pathways of metabolism and synthesis. Additionally,
several mRNAs demonstrated altered regulation at 30 minutes after injury; these were
primarily made up of IEGs such as Fos, Jun, and Arc that were associated with
downstream inflammatory and apoptotic pathways on KEGG analysis. Finally, Chapter 3
demonstrated that treatment with intranasal hypoxia preconditioned EVs resulted in
neuroprotection following neonatal HIBI. These preconditioned EVs contained 24 miRNAs
– many of which are involved in apoptotic pathways – that were at concentrations high
enough to be consistently identified by miRNA sequencing.
Effects of Hypoxia Only Versus HIBI on Brain MicroRNA Expression
Given the significant role of hypoxamiRs in regulating the cell response to hypoxia, it
is not surprising that many of the known hypoxamiRs (including miR-135a, -34a, -21a, 369, -128, and -92) (136, 137) demonstrated significant differential expression in the
hypoxia only group versus controls in Chapter 1. The direction of differential expression
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was consistent between 24 and 72 hours after hypoxic injury (as compared to HIBI where
many of the miRNAs showed inverse differential expression at 24 versus 72 hours).
Although there are very few time-series studies assessing temporal changes in miRNA
expression after hypoxia, those that have been published demonstrate similarly persistent
expression of hypoxamiRs up to 48 hours after hypoxia (138, 139).
In the current study, the primary value of assessing miRNA expression after hypoxia
was in the comparison with the miRNA expression after HIBI in order to better understand
the contribution of hypoxia versus ischemia in driving miRNA expression.
Temporal and Regional MicroRNA Changes After HIBI
In the HIBI tissue, four highly conserved miRNAs demonstrated significant differential
expression at both 24 and 72 hours after injury: miR-2137, -335, -137, and -376c. Of these,
miR-2137 was the only HIBI-specific miRNA that was upregulated at both 24 hours and
72 hours after injury.
MiR-2137 is involved in inflammation, has been associated with elevated levels of
TNF-⍺, and its inhibition has been shown to increase the anti-inflammatory interleukin IL10 (140). Increased miR-2137 expression has also been shown in the penumbral tissue
after traumatic brain injury (141) and a previous study demonstrated upregulation of miR2137 up to 7 days after injury in an adult ischemic stroke model (142). Contrary to our
findings, however, the post-stroke data showed a decrease in miR-2137 differential
expression between 1 and 3 days after injury while ours demonstrated an increase. This
difference may be due to developmental differences between neonatal and adult brains,
but could also be due to differences in the methodology of inducing HIBI in the neonatal
versus adult models. It is notable that miR-2137 is the only of the four key miRNAs
identified in HIBI in our study that has not yet been described as a hypoxamiR, and its
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differential expression after HIBI was inverse to that of the hypoxia only group at both 24
and 72 hours, suggesting a unique association with ischemia rather than hypoxia.
Additionally of note, miR-2137 is also significantly increased after ischemic cardiac injury
(143), suggesting that its inhibition could have beneficial effects outside of the brain as
well.
Consistent with the triphasic pattern seen in the pathophysiology of neonatal hypoxicischemic encephalopathy, we demonstrated
multiphasic differential expression in several of
the key HIBI-related miRNAs (Figure 22),
including miR-335. MiR-335 is a hypoxamiR,
regulates cholesterol metabolism (144-146),
and acts as a direct regulator of HIF1⍺ as well
as being predicted to regulate several other
mRNA known to be affected by neonatal HIBI
(Table 1). MiR-335 has been shown to be

Figure 22. Change in differential
expression (DE, hypoxic-ischemic
brain injury vs. control) over time for
microRNAs (miRNA) with DE at more
than one time point demonstrating the
tri-phasic expression of many of the key
miRNAs.

downregulated in the cord blood of infants who
suffered moderate to severe HIBI (22) and remains altered at 1-2 months after injury in
infants with intraventricular hemorrhage and resulting abnormal muscle tone (147). In the
adult stroke model, miR-335 has been shown to have a triphasic expression pattern:
downregulated immediately after middle cerebral artery occlusion, peaked upregulation
around 24 hours, and then downregulation again after 24 hours. Reflecting this pattern,
miR-335 mimic has been shown to be neuroprotective when administered immediately
after injury, when endogenous miR-355 expression is lowest, but miR-335 antagonist was
neuroprotective when administered at 24 hours after injury, corresponding to increased
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endogenous expression (35). The current data showed similar trends, with upregulation
at 24 hours after HIBI but downregulation by 72 hours.
In addition to miR-335, miR-376c was also seen in previous studies of cord blood after
perinatal asphyxia or neonatal hypoxic-ischemic encephalopathy (21, 103). The relative
downregulation of miR-376c demonstrated in the cord blood studies, in conjunction with
relative upregulation at 24 hours and downregulation at 72 hours after HI injury in the
current study, suggests that miR-376c also may have a triphasic response. This is further
supported by an in vitro study demonstrating that overexpression of miR-376c-3p at the
time of oxygen-glucose deprivation increased cell viability and decreased apoptosis by
inhibiting inhibitor of growth family member 5 (ING5) in two neuroblast cell lines (148).
miR-137 is another hypoxamiR that has also been associated with the inflammatory
response after cerebral ischemia (149). miR-137 may also play a significant role in brain
development and neural stem cell differentiation (150), with decreased levels of miR-137
during brain development being associated with increased anxiety-like behaviors later in
life (151). During brain development, miR-137 is known to be highly expressed, specifically
in the dorsolateral nucleus and ventral posterolateral nucleus of the thalamus, the
striatum, the nucleus accumbens of the telencephalon, and the cerebral peduncles (152);
a spatial distribution suggesting a relationship with cholinergic neurotransmission
neurons. Similar to the pattern observed in miR-335, the current study results showed
upregulation of miR-137 at 24 hours after HIBI but downregulation at 72 hours. Although
the multiphasic expression is not as well described as that of miR-335, it is likely that miR137 also has a triphasic pattern, since overexpression of miR-137 at 30 minutes after
cerebral ischemia attenuated brain levels of JAK1, STAT1, TNF-⍺, IL-1β, and IL-6 and
resulted in decreased infarct size and neurological function score, suggesting that levels
were low or downregulated early after ischemia (149).
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As mentioned in the introduction, miR-210 is one of the most commonly studied
hypoxia-related miRNAs and has been found to be elevated in rat brain after neonatal
HIBI at 3 hours up to 24 hours (39). Although none of the studies presented here
demonstrated significant changes in miR-210, there was a non-significant (1.8-fold,
p=0.057) increase in HIBI versus controls at 72 hours after injury. This underscores the
potential limitations from the smaller sample sizes in these studies, which may miss some
physiologically relevant miRNAs. Additionally, as miR-210 has been closely associated
with the effects of hypoxia, differences in oxygen concentrations and duration may affect
its differential regulation. For instance, rat pups and some strains of mice, such as 129Sv,
have been found to be more resistant to hypoxia-ischemia and so must receive longer
and/or deeper hypoxia to result in the necessary brain injury to model HIBI (94).
An additional limitation of cross-species miRNA analyses (i.e. using rodent studies to
design human interventions) is that miRNAs differ between species. Each of the studies
above addressed the known conservation of miRNAs between mammalian species in the
miRNAs that were detected, but there still exists the possibility of missing a pathologic
miRNA that exists in humans but not in rodents. This is likely the case with miR-374a
which was significantly altered in the Looney, et al umbilical cord blood study as well as
that group’s follow-up study, but miR-374a has not yet been identified in the house mouse
(Mus musculus), so the sequencing alignment performed in these studies would not have
identified it. Of note, however, miR-374b, which has a sequence with 96% similarity to
miR-374a, was upregulated in HIBI versus controls at 24 hours in the current studies.
The final conclusions from chapters 1 and 2 centered around the use of various
internal controls for this neonatal HIBI model. First, in chapter 1, the clustering analyses
revealed distinct miRNA signatures between the sample groups, which were quite different
at 24 and 72 hours. They suggested that the early subacute phase of the injury (at 24
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hours) continues to evolve and change, giving rise to a less extensive, but more robust
miRNA profile in HIBI animals at 72 hours. Additionally, the data suggested that using the
contralateral hemisphere of the lesioned animals as a baseline control in the first 24 hours
after HIBI is perhaps less than ideal. The unilateral lesion appears to have a strong effect
on the miRNA expression level of the whole brain, and not only on the lesioned side.
Contrary to the contralateral findings, in chapter 2, the cerebellum demonstrated distinct
miRNA signatures at 30 minutes after injury, so may serve as an effective internal control
at least in the immediate period after injury.
Downstream Pathways of Key MicroRNAs
Chapter 2 measured early mRNA expression levels after neonatal HIBI and
demonstrated that, in the early phase of injury, there was limited clear interaction between
miRNAs expressed at that time point and mRNA expression. Instead, most of the mRNAs
that demonstrated significant differential expression were IEGs, including Atf3, Fos, Arc,
Jun, and Tlr; IEGs that are largely involved in inflammatory and cell death pathways,
including interleukin (IL-3, -8, -10, -17A), TNF receptor, HIF1⍺, and PI3K signaling. IEGs
are genes that are rapidly transcribed in response to positive (e.g. neuronal activity) or
negative (e.g. injury) stimuli and often ask as transcription factors and DNA-binding
proteins (153). The regulation of the IEGs is complex but, of importance for the current
studies, is closely tied with miRNA expression. IEGs can directly regulate the expression
of various miRNAs (154). Specifically, Atf3 expression has been shown by multiple
investigator groups to be regulated largely by a negative miRNA-based feedback loop
(155, 156). Stimulating IEG expression briefly inhibits production of the negative feedback
miRNAs (155, 156). This feedback relationship is a likely cause of the lack of predicted
miRNA-mRNA interaction seen in Chapter 2; when IEGs are highly expressed, their
associated miRNAs are repressed, and vice versa.
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In each of the three chapters, additional predictions of miRNA targets were performed
through KEGG pathway analyses. In Chapter 2, compared to the IEG mRNA expression
described above, the miRNA KEGG analysis demonstrated that the miRNAs with altered
regulation were primarily associated metabolic pathways, including that of fatty acid
metabolism and biosynthesis, lysine metabolism, steroid biosynthesis, AMPK signaling,
and sphingolipid metabolism. Many of the traditional hypoxia and cell death pathways,
including mTOR, MAPK, and HIF1 were also present as significant targets in the KEGG
analysis, but had considerably lower -log(p value) values.
For chapters 1 and 2, the KEGG pathways that were significantly associated with the
differentially expressed miRNAs at all three time points are demonstrated in Figure 23.
Overall, there were 23 pathways that were consistently targeted at 30 minutes, 24 hours,
and 72 hours after injury. Twenty of the 23 pathways were also significantly associated
with the miRNAs that were detected within the hypoxia preconditioned EVs in chapter 3.

Figure 23. KEGG pathways consistently affected throughout the first 72 hours after
injury. KEGG pathway analyses performed by Diana-miRPath for miRNAs with significant
differential expression at each time point. Figure lists all pathways demonstrating statistical
significance at all three time points. *Pathways also significantly associated with miRNAs that
were identified in neuroprotective hypoxia-preconditioned extracellular vesicles.

Although there are many different pathways, many of them are closely associated with
three of the primary pathways: the MAPK, mTOR, and PI3K-Akt signaling pathways.
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MAPK Pathway
The MAPK pathway primarily consists of three families of genes: ERK, JNK/SAPK,
and p38 MAPK. Each of these three sub-pathways can affect cell proliferation and
differentiation, while the p38 and JNK/SAPK can also affect apoptosis, and p38 uniquely
alters inflammation and stress response (157). The MAPK pathway is also closely linked
to several other relevant pathways, including inhibiting the FoxO signaling pathway,
stimulating the neurotrophin pathway and being stimulated by the Rap1 signaling pathway.
Of the miRNAs highlighted in the current studies, miR-335, -137, -376c, -1264, -1298, 34b, -3473a, and -3473b are all predicted to target genes in the MAPK pathway. For
instance, miR-335 and -34b are predicted to affect Rasa1 in the classical MAPK ERK
pathway while miR-376c, -1264, -335, and -34b also target Map3k2 in the JNK pathway.
Both the ERK and JNK pathways have previously been shown to be targets for
neuroprotective intervention after neonatal HIBI. Inhibition of the JNK pathway with the
specific inhibitor TAT-JBD reduced neuronal injury and caspase-3 levels in the hours after
neonatal HIBI as well as attenuating white and grey matter injury at 14 weeks after injury
(158). For the ERK pathway, multiple studies in the rat model have demonstrated that the
increased activation of ERK after neonatal HIBI can be neuroprotective (159-161). One
study in the piglet model showed no difference in gross neuropathology after modulating
the ERK pathways (162), but they used an ERK inhibitor rather than increasing activation,
which primarily demonstrates that further inhibiting the ERK pathway (which is already
downregulated by HIBI) does not further injure the brain.
mTOR Pathway
mTOR is a downstream kinase that can be activated by the PI3K/Akt, MAPK ERK, and
AMPK signaling pathways, but can also be separately altered by several of the individual
miRNAs that were found to be significantly altered in the current studies. Rapamycin-
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insensitive companion of mTOR (Rictor), which codes for one of the protein components
of the mTOR complex, is a predicted target of miR-137 and -1264. Rictor knockouts
impairs brain development, resulting in decreased brain size, smaller neuronal somas,
and shorter dendritic processes (163). Additionally, inhibition of mTOR complex 2 by
Rictor deficiency has been shown to exacerbate ischemia reperfusion injury in the liver
(164), but the role of Rictor specifically in brain hypoxia-ischemia has not yet been
evaluated. One of the most well-studied of the mTOR pathway targets is HIF1⍺, which is
directly activated by mTOR and is also a predicted target of miR-376c and -6240.
HIF1⍺ is the 3’ enhancer of the erythropoietin gene and contains three domains: the
N-terminal domain, the C-terminal transactivation domain which primarily regulates gene
transcription activity, and an oxygen-dependent degradation domain which mediates
oxygen-dependent stability (165). As mentioned above, HIF1⍺ expression demonstrates
a multiphasic response after neonatal HIBI, with significant upregulation at 4-12 hours,
decreasing to near-baseline by 24 hours and then subsequent elevation again between 2
and 8 days after injury (166). Although it is known to play a central role in hypoxic and
hypoxic-ischemic brain injury, many questions still remain regarding the precise
mechanisms by which HIF1⍺ modulates brain injury after neonatal HIBI. For example,
while acute HIF1⍺ upregulation induces cellular apoptosis by both increasing the stability
of p53 (167) and inducing expression of the BCL2/adenovirus E1B interacting protein 3
(BNIP3) (168), chronic upregulation of HIF1⍺ through hypoxia preconditioning results in
anti-apoptotic effects (169, 170), potentially through increasing erythropoietin expression
(170) and/or increasing anaerobic metabolic potential (171). The neuroprotective effects
of hypoxia preconditioning are not completely dependent on HIF1⍺, however, as the
positive effects of preconditioning are retained in HIF1⍺-deficient mice (166).
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Several studies have specifically assessed the role of endogenous HIF1⍺ and the
potential protective effects of downregulating HIF1⍺ in neonatal HIBI. Inhibition of HIF1⍺
using the inhibitor 2-methoxyestradiol immediately after HIBI resulted in decreased brain
infarct volume, brain edema, and blood-brain barrier disruption (172). Contrary to these
findings, however, neuron-specific HIF-1⍺ knockout mice developed more necrotic and
apoptotic cell death than control mice after neonatal HIBI (173). It is very possible that this
contradiction could be explained by the non-specific nature of 2-methoxyestradiol
inhibition. A study in an adult stroke model suggested that HIF1⍺ knockout mice had no
change in infarct or edema size, but when both HIF1⍺ and HIF2⍺ were knocked out, they
demonstrated significantly reduced cell death and edema after ischemic brain injury (174),
suggesting that the benefits seen in the 2-methoxyestradiol study may have been due to
the drug’s ability to inhibit both HIF1⍺ and HIF2⍺ (175).
PI3K-Akt Pathway
The PI3K-Akt pathway is involved in regulating cellular activation, inflammatory
response, and apoptosis (176). Akt is the primary downstream effector in the pathway,
and its activation promotes the phosphorylation of several downstream molecules,
including Bcl-2, Fox03a, and mTOR, which each then act to reduce apoptosis (177).
Several of the miRNAs that were highlighted in the current studies were closely associated
with the downstream mRNAs from Akt. These include Casp9 (miR-137 and -3473a),
Creb1 (miR-6240 and -410), and Bcl2 (miR-1264, -3473a, and -6240). Much like the other
pathways already discussed, the PI3K-Akt pathway is also closely linked with several
other pathways identified in the KEGG pathway analysis. The PI3K-Akt pathway can be
activated by the RAP1 or ErbB signaling pathways and can in turn inhibit the FoxO
signaling pathway.
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Neonatal HIBI has been shown to result in inhibition of the PI3K-Akt signaling pathway.
Further inhibition of PI3K by the inhibitor LY294002 in a rabbit model exacerbated
neurological impairment beyond that seen in the injured controls (178). Additionally,
LY294002 partially reversed the neuroprotective effects seen after administration of
liraglutide (179) or L-cysteine (180), and the Akt inhibitor wortmannin did the same for the
neuroprotective effects of progesterone (181) in the rodent models of neonatal HIBI,
demonstrating the significant role that the PI3K-Akt pathway plays in neuroprotection.
Circadian Rhythm Pathway
Given the cyclical patterns of the miRNA expression it is not surprising that many of
the miRNAs that were found to be altered after neonatal HIBI were related to the circadian
rhythm pathway. Neonatal HIBI results in impaired circadian rhythms, likely in part due to
decreased pineal melatonin levels (182). Clock protein, which is thought to be the master
regulator of the circadian rhythm and is predicted as a target for both miR-335 and miR182, was found to be upregulated after neonatal HIBI versus controls, but not until ~48
hours after injury (183). Melatonin levels, however, were decreased within the first 8 hours
of injury (182), and one of the primary nuclear receptors of melatonin, retinoic acid
receptor-related orphan receptor A (Rora), is a predicted target for miR-1264 and -137.
Although not one of the miRNAs that demonstrated significant differential expression in
the current studies, peripheral blood mononuclear cell levels of miR-325 have been
positively associated with increased sleep rhythm problems in human infants after HIBI,
and miR-325 knockout resulted in improved circadian rhythmicity and motor outcomes in
mice after neonatal HIBI (184), suggesting that the circadian rhythm pathway may be yet
another potential therapeutic target for neonatal HIBI.
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Metabolic Pathways
One of the primary deficiencies in neonatal HIBI is metabolic failure, and as such, it is
important to also consider the metabolic and synthetic pathways that may be altered by
miRNAs. These include the ceramide and glycosphingolipid synthetic pathways which are
known to be altered by HIBI, with decreased ceramide and sphingomyelin levels present
for up to seven days after preterm HIBI (185). The glycosphingolipid pathways are
predicted to be altered by miR-6240 and -125a-5p (which inhibit Fut1) as well as miR-1825p and -1264-3p (which inhibit Fut9). Sterol synthesis and metabolism has also been
found to be altered after neonatal HIBI (186) and is associated with several of the key
miRNAs from the current study. For example, miR-335 expression is associated with
decreased 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and synthase (HMGCS),
suggesting a key role in astrocyte cholesterol synthesis (144), and may also affect
lanosterol synthase and sterol-C5-desaturase (146). Similarly, miR-148a regulates LDL
receptor and ABCA1 (187) and, along with the other miRNA modulators of the AMPK
pathways (which includes 14 of the key miRNAs from the current study) may inhibit
HMGCR (188).
High-Yield MicroRNAs for Future Neuroprotective Studies
Several promising miRNAs can be derived from the current studies, including miR2137, -335, -137, and -376c from Chapter 1 and miR-410, -1264, -1298, -5126, -34b, 6240, -3963, -3473a, and -3473b from Chapter 2. Lastly, in Chapter 3, the miRNAs that
were highly expressed in the neuroprotective EVs include miR-92b, -541, -434, -328, 342, and -361. Figure 24 demonstrates the clustering relationships between all of the
miRNAs from chapters 1-3. Although the miRNA profiling in the first two chapters provides
increased insight into the pathophysiology of neonatal HIBI and offers several potential
high-yield targets for future therapeutic studies, it is important to note two significant
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limitations: 1) differential expression of a miRNA after HIBI is not equivalent to pathologic
expression, and 2) a lack of differential expression in a miRNA does not rule out
therapeutic potential. The latter point is probably best exemplified by miR-210 which, as
described in the introduction, has been demonstrated to be an effective target in multiple
studies of neonatal HIBI and yet was not differentially expressed at any of the three time
points assessed. This is often the case in the body’s stress response, where the lack of
upregulation (e.g. adrenal insufficiency resulting in a lack of cortisol elevation during
stress) is pathologic.
Additionally, despite the inability
of studies in the mouse model to
detect human-specific miRNA such
as miR-374a, it may still be possible
to test the therapeutic potential of
human-specific

miRNA

interventions in the rodent model. As
an example, one study using the rat
model

of

neonatal

HIBI

demonstrated significant attenuation
of inflammatory cytokines and brain
injury after intracerebroventricular
injection of miR-374a-5p mimic (62).
These investigators developed a

Figure 24. Hierarchical cluster pathway
dendrogram of the promising miRNAs from
chapters 1-3. Pathway analyses performed by
Diana-miRPath.

mimic from the human hsa-miR374a-5p and still demonstrated improvement in injury despite the rat, like the mouse, not
having an identified rat-specific rno-miR-374a.
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Given the pre-clinical results already performed, both miR-210 and -374a certainly
deserve continued attention in neonatal HIBI research despite their absence in the current
studies. Further studies will be necessary to better identify potential stress response
miRNAs that are not included in the following list of high-yield miRNAs for future studies
of neuroprotective interventions. Since neonatal HIBI is a complex and multifactorial injury,
developing effective therapies requires consideration of targeting multiple key pathways.
As such, the following miRNAs are separated based on the pathway clusters in Figure 24.
Cluster 1
The miRNAs in this cluster target pathways including GABAergic synapse
development, axon guidance, cGMP-PKG signaling pathway, and glycosphingolipid
biosynthesis. Firstly, mir-182-5p was significantly downregulated at 24 hours after injury
in whole brain, returns to control levels by 72 hours, and was detected in modest numbers
in the preconditioned EVs. These findings are consistent with persistent downregulation
that was seen for the first 48 hours after hypoxia plus inflammation induced by LPS (129)
as well as a 5-fold downregulation at 48 hours after preterm HIBI (189). Additionally, miR182 was downregulated at 12, 24, and 48 hours after HIBI in the neonatal rat model, and
administration of miR-182 mimic to pineal gland cells after OGD resulted in attenuation of
Clock protein elevation after injury (190) and thus miR-182 alterations may contribute to
some of the circadian rhythm abnormalities that can be seen after neonatal HIBI.
Although not demonstrated to have significant differential expression at any of the
three time points in the current study, miR-330 was expressed at a moderate level in the
preconditioned EVs. Although its role in hypoxic and/or ischemic injury has not yet been
explored in the literature, it may play a role in inflammation given that it was found to be
consistently downregulated for the first 48 hours in the blood of a piglet model of neonatal
hypoxic brain injury plus inflammation induced by LPS (129). Specifically, miR-330
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expression was significantly lower in the hypoxia+LPS group compared to hypoxia alone.
Its expression may also be developmentally regulated, as miR-330 was also
downregulated 7-fold at 48 hours after preterm HIBI (189). Lastly, although it has been
shown to inhibit Egr2 (191) which is a key protein in peripheral myelination (192), miR-330
expression does not appear to modulate myelin formation in the central nervous system
(193).
miR-3473b expression was found to be upregulated in the striatum, thalamus, and
cortex at 30 minutes after injury and remained significantly elevated at 72 hours. A study
in BV2 microglial cells showed that miR-3473b induces pro-inflammatory factors such as
inducible nitric oxide synthase (iNOS), COX-2, TNF-⍺, and IL-6 by targeting SOCS3 (194)
and inhibits autophagy through TREM2 and ULK1 expression (195). Another possible
mechanism of miR-3473b in neonatal HIBI is its effects on PTEN (196), a gene closely
linked with the master hypoxia regulator HIF1⍺. Either pathway would suggest that
downregulation of miR-3473b could attenuate cellular injury after HIBI.
Chapter 2 demonstrated significant increased expression of miR-1298 in the cortex,
striatum, and thalamus at 30 minutes after injury, though a study using an adult model of
brain hypoxia-ischemia demonstrated decreased expression in HIBI versus controls at 24
hours after injury, suggesting a multi-phasic expression (197). The physiologic targets and
effects of miR-1298 in the brain, however, are still unknown at this time. Additionally, mir6240 was significantly upregulated in the cortex and cerebellum at 30 minutes and
remains elevated throughout the first 72 hours after injury, with significant elevation at 72
hours in the whole brain. It was also expressed in moderate quantity in the preconditioned
EVs. Similar to miR-1298, though, little is known about the effects of miR-6240 expression
outside of the in silico predicted effects.
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Cluster 2
Some of the main pathways affected by the miRNAs in this cluster include the AMPK
signaling pathway, galactose metabolism, and glycosphingolipid biosynthesis; all
pathways related to metabolism and energy maintenance. This cluster includes miR-125a
which targets Ppp2ca, a direct inhibitor of AMPK, as well as Fut1, a main driver of
sphingolipid metabolism. miR-125a was downregulated in the cerebellum at 30 minutes
after HIBI, but not the striatum or thalamus, suggesting that it is altered more by hypoxia
(given that the cerebellum does not undergo ischemia in the mouse model) than ischemia,
which is also supported by its significant downregulation at 24 hours after injury in hypoxiaonly brains versus controls but not HIBI versus controls. Despite the endogenous
downregulation of miR-125a after neonatal hypoxia in the current study, it may be that
further inhibition of miR-125a – rather than upregulation – is actually therapeutic, as miR125a silencing in an adult ischemic stroke model resulted in suppression of apoptosis
through targeting of insulin-like growth factor binding protein 3 (IGFBP3) (198) and/or
tissue inhibitor matrix metalloproteinase 1 (TIMP-1) (199). Additionally, miR-125a is highly
expressed in cerebral spinal fluid (200), so could act as a potential cerebral spinal fluid
biomarker.
The second miRNA in this cluster, miR-3473a, was upregulated in all three regions of
the brain at 30 minutes after HIBI in the current study. It appeared to only be altered in the
acute phase after injury, as it was not differentially expressed at 24 or 72 hours after injury.
Although not much is known about its specific role in the brain, miR-3473a was one of the
miRNAs found to be downregulated in the brain after preconditioning, suggesting that the
relative decrease in expression may play a role in the neuroprotective effects of
preconditioning (201).
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miR-1264 also demonstrated increased expression in the cortex, striatum, and
thalamus at 30 minutes after HIBI but, like miR-3473a, was only differentially expressed
in the acute injury phase and returned to control levels by 24 hours. In adult stroke,
upregulated miR-1264 expression was noted immediately after injury, peaking around 3
hours after injury, and gradually decreasing, remaining upregulated at 12 hours but not
significantly altered at 24 hours after injury (202). Inhibition of miR-1264 attenuates
apoptosis through targeting WNT/β-catenin signaling (203).
Cluster 3
For this cluster, the included miRNAs target the MAPK signaling pathway, biosynthesis
of unsaturated fatty acids, circadian rhythm, and GABAergic synapse regulation. miR-137
has already been described in depth above.
miR-410 was found in the current studies to be downregulated in the cortex and
upregulated in the cerebellum at 30 minutes after injury, with no differential expression at
24 or 72 hours. It was also downregulated in umbilical cord blood (21) as well as in
circulating blood within 6 hours after delivery (30) in infants diagnosed with HIE.
Overexpression of miR-410 attenuated apoptosis and inflammation in OGD models using
both PC12 and SH-SY5Y cell lines (30). Furthermore, mesenchymal stem cell derived
EVs that were neuroprotective when injected intraperitoneally after neonatal HIBI lost their
positive effects on cerebral edema and infarct size after treatment with miR-410 antagonist
(87).
miR-376c was found in the current studies to have increased expression at 24 hours
and decreased expression at 72 hours after injury. Overexpression of miR-376c has been
associated with increased cell viability, in part due to inhibition of ING5 (148). Although
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miR-376c has been evaluated in several oncological studies, its role in brain development
and/or injury has not yet been well defined.
Cluster 4
This final cluster includes six miRNAs that target pathways including FoxO signaling,
PI3K-Akt signaling, and glutamatergic synapses. miR-2137 and -335 have already been
described in depth, but mir-342 also has considerable promise as a therapeutic target, as
it was significantly downregulated at 24 hours after injury in whole brain in the current
study and was also highly expressed in the preconditioned EVs. Previous studies also
showed miR-342 expression was downregulated in human umbilical cord blood at the time
of neonatal HIBI (22) as well as in the blood after stroke in adults (204). Despite the several
studies demonstrating its alterations, however, little is known about its true function in the
brain.
One of the miRNAs that was highly differentially expressed at all three time points in
the current study was miR-5126, which was upregulated in the cortex at 30 minutes and
remained significantly upregulated in the whole brain at 24 and 72 hours after HIBI. It was
also found to be downregulated in the cerebellum at 30 minutes, suggesting that it may
be able to help differentiate between hypoxia only and HIBI, which is further supported by
the finding that miR-5126 has significantly higher expression in HIBI versus hypoxia only
at 24 hours (logFC 3.6) and 72 hours (logFC 5.7) after injury. This prolonged elevated
expression and specificity for HIBI make miR-5126 an attractive candidate for a
therapeutic target; however, it is unclear whether miR-5126 is adequately conserved
between mammalian species.
miR-34b demonstrated increased expression in the striatum and thalamus at 30
minutes after HIBI and, although not differentially expressed at 24 hours, was significantly
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increased again at 72 hours. Although the effects of miR-34b in the brain are not well
known, it has been shown to increase cell apoptosis through increased p53 and Bax and
decreased BCL2 (205). The final miRNA in this cluster, miR-3963, was upregulated in all
three regions at 30 minutes but not at 24 hours or 72 hours. Although it has been found to
be highly upregulated in microglia in the developing brain (206), it has unfortunately not
been well studied and it’s conservation between species is not known.
Conclusions
The current studies identified several promising miRNAs for future investigations into
miRNA-based therapeutic interventions. Given the multifactorial nature of neonatal HIBI,
it is likely that a combination of miRNAs would need to be targeted to achieve maximal
benefit. Because of this, the list of promising miRNAs was grouped by targeted pathways,
and future investigations should consider assessing the effects of altering one or more
miRNA from each of the miRNA clusters. Additional mechanistic studies will be necessary
to demonstrate whether the differential expression seen in chapters 1 and 2 are beneficial
or pathologic and whether the miRNAs detected in the EVs in chapter 3 play a significant
role in the neuroprotection seen after hypoxia preconditioned EV administration. Lastly, in
order to better translate the pre-clinical miRNA studies to human infants, more sensitive
analyses of postnatal circulating miRNAs must be performed. One possible method for
specifically assessing brain-related miRNA expression could be identifying the miRNAs
contained within circulating EV carrying brain-specific markers such as neuronal L1 cell
adhesion molecule (L1CAM) (207). Ultimately, given their broad effect profile, ease of
administration, and small size allowing for effective blood-brain barrier crossing, miRNAs
represent promising targets for improving brain injury and reducing developmental
impairments in neonates suffering from HIE.
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